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ABSTRACT
Inflammatory bowel disease (IBD), comprised of Crohn’s disease (CD) and
ulcerative colitis (UC), is chronic inflammation affecting more than 1.5 million people in
the United States and 2.2 million people in Europe. CD can affect any portion of the
gastrointestinal (GI) tract and is commonly patchy with a transmural inflammation
pattern. UC is limited to the large intestine and has a continuous inflammatory pattern
that involves only the mucosa. A commonality is a dysregulated immune response in
the intestine. IBD develops in genetically susceptible individuals due to complex
interactions between environmental stimuli, genome, microbiome, and an inappropriate
mucosa immune response. However, the current treatment is not effective enough to
show significant improvement in many patients. Here, we developed two therapeutic
approaches to treat intestinal mucosal wounds found in ulcerative colitis in vitro and in
vivo.
In the first section, I studied fecal metabolites derived from genetic knockout (KO)
of peptide transporter-1 (PepT1) mice which are known to show resistance to acute
colitis and colitis-associated cancer (CAC). The previous publication provided evidence
that the PepT1 KO microbiota is sufficient to protect against colitis and CAC. Given that
PepT1 KO alters the gut microbiome and thereby changes the intestinal metabolites
that are ultimately reflected in the fecal samples. Therefore, we investigated the fecal
metabolites of PepT1 KO mice using a liquid chromatography-mass spectrometry (LCMS)-based untargeted metabolomics technique. We found that the specific fecal
metabolite, tuberonic acid (TA), increased seven times higher in KO mouse fecal
samples when compared to wild-type (WT) mouse feces. Accordingly, we performed

research on whether the increased TA could have an anti-inflammatory effect. In vitro
study discovered that TA not only prevented lipopolysaccharides (LPS)-induced
inflammation in macrophages but also accelerated the epithelial cell healing processes.
In the next section, we studied mRNA-based therapeutics using lipid nanoparticle
encapsulation. Inspired by the colon-targeting ability of ginger-derived nanoparticles
(GDNPs) from our laboratory, we reversely engineered lipid nanoparticles (LNPs) that
comprise the most abundant lipids in GDNPs, including phosphatidic acid (PA),
monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG) at 5:2:3
ratio. We encapsulated IL-22 mRNA within the newly generated lipid nanoparticles
(nLNPs) as enhanced IL-22 expression in the colon is known to have a potent antiinflammatory effect against ulcerative colitis (UC). The IL-22 mRNA-loaded nLNPs were
shown to be approximately 200 nm in diameter and have a zeta potential of -18 mV.
Oral administration of the IL-22/nLNPs complex increased the protein expression level
in the colonic mucosa. During acute colitis, mice fed with the IL-22/nLNPs experienced
an accelerated healing process, as indicated by the recovery of higher body weight and
longer colon length as well as reduction of colonic MPO activity, fecal lipocalin
concentration, histological index, and mRNA expression level of pro-inflammatory
cytokines (TNF-α, IL-6, and IL-1β). These results indicate that the reversely engineered
nLNPs are an effective mRNA delivery system to treat ulcerative colitis.
The last two sections elaborate on two different protocols to generate and
characterize novel, natural, non-toxic ginger-derived nanoparticles (GDNPs) and gingerderived lipid vesicles (GDLVs) that can be utilized as well-defined drug vehicles for
treating inflamed intestinal mucosa. The first method uses sucrose gradient

ultracentrifugation with extracted ginger juice to purify GDNPs. The concentration of
obtained GDNPs was measured by a protein quantification assay kit and microplate
reader at an absorbance of 750 nm. The second method uses liquid-liquid extraction to
isolate lipid vesicles from GDNPs from the first protocol. Ginger-derived lipid vesicles
(GDLVs) were generated by thin-film hydration and dissolved therapeutic agent, siRNA,
by brief suspension by sonication. This GDLVs/siRNA complex was measured for its
size and zeta potential, then its TEM and AFM images were acquired. In addition, in
vivo test was performed to ensure its delivery functionality, bio-distribution, and
efficiency. These two protocols provide a novel and crucial method to develop an
efficient and safe drug delivery system that causes no immunotoxicity when orally
administered. Furthermore, the nanostructure of GDNPs is the primary source of
reversely engineered lipid nanoparticles for the mRNA-loaded delivery system (Page
41).
In conclusion, these therapeutic studies prove that the two different approaches
of treating fecal metabolite and IL-22-loaded lipid nanoparticles to accelerate the
healing process of intestinal inflammation are effective both in vitro and in vivo.
Metabolites have emerged as essential effectors in mediating commensal microbiomes
in human physiology. Positive results to show the anti-inflammatory effect of the specific
metabolite derived from genetic knockout of PepT1 could be the groundwork of novel
metabolites-based therapies. Safe and efficient RNA-based gene therapy using lipid
nanoparticles was propelled into the spotlight due to the pandemic outbreak. The shortterm oral administration of IL-22 mRNA protected by nLNPs successfully demonstrated

a powerful mucosal healing effect. This may provide a potent gene therapy to treat
ulcerative colitis.

INDEX WORDS: ulcerative colitis (UC), peptide transporter 1 (PepT1), fecal
metabolites, tuberonic acid (TA), IL-22 mRNA, lipid nanoparticles (LNPs),
intestinal microbiota
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1 INTRODUCTION
1.1 Inflammatory Bowel Disease (IBD)
Inflammatory bowels disease is a relapsing and chronic inflammatory disorder in
the gastrointestinal (GI) tract with two major clinical phenotypes, ulcerative colitis (UC)
and Crohn’s disease (CD). We do not have a sufficient understanding of the
pahogenesis of IBD; therefore, effective diagnosis and therapeutics of such diseases
are difficult to be exploited due to non-specific symptoms and various causing factors.
The symptoms can be diagnosed by physical examinations, a combination of blood
tests, and an endoscopy of the colon. These techniques are not ideal for patients
because they are costly, invasive, and burden the human body. Current IBD treatment
mainly focuses on inhibiting pro-inflammatory cells and cytokines. The most popular
therapeutic agents treated for patients are anti-tumor necrosis factor (TNF) and antiintegrin. However, these treatments may not always work on every patient and often
accompany short- and long-term adverse effects, including bacterial/fungal infection,
cancer development, and increased mortality.
1.1.1 Ulcerative Colitis
Ulcerative colitis is an idiopathic and chronic inflammatory condition of the colon
which result in superficial erosion on the colonic wall. It involves inflammation restricted
explicitly to the innermost lining, mucosa, and submucosa of the colon layer. It usually
starts in the rectum and extends proximally in a continuous manner through the colon.
Characteristic symptoms of the disease include diarrhea, rectal bleeding, abdominal
pain, inability to defecate, weight loss, and fatigue. North America and northern Europe
have the highest incidence, and prevalence rates with incidence differ from 9-20 cases
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per 1,000,000 people annually and prevalence rate from 156-291 cases per 100,000
people (Ordas, Eckmann, Talamini, Baumgart, & Sandborn, 2012). The incidence of the
disease is related to an industrialized lifestyle, suggesting that environmental factors
could be critical for onset.
1.1.2 Crohn’s Disease
Crohn’s disease is a chronic transmural inflammatory bowel disease that usually
affects the distal ileum and colon, but it could occur in any part of the gastrointestinal
tract (GIT). It begins with crypt inflammation and abscesses. The mucosal lesions
develop into deep longitudinal and transverse ulcers creating a cobblestoned
appearance to the bowel. About 1/3 of CD patients have small bowel involvement,
another 20% have only colon involvement, and approximately half have both involved
(Ranasinghe & Hsu, 2022). The exact etiology of CD is well known, but there is
evidence to suggest that the disease results from abnormal immune responses in the
bowel, and some environmental factors such as drugs, toxins, infections, or gut
microbes may cause problems in a genetically susceptible individual. There are more
than a hundred genes identified to have an association with CD. Specifically,
NOD2/CARD15 mutations were closely related to the CD phenotype (Ranasinghe &
Hsu, 2022). Its incidence is mainly detected in the western developed countries in North
America, northern Europe, and New Zealand. The onset of CD is frequently seen in
people aged between 15 to 30 years and 40 to 60 years old. There is a report that the
high incidence in North America and Europe compared to those in Asia, Africa, and
South America. However, recent studies show a significant increase in CD in rapidly
industrial areas in Asia, Africa, and Australia (Petagna et al., 2020).
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1.2 Current Therapeutics of IBD
The current therapeutic paradigm for moderate to severe CD and UC is to use
biologics in the early stage to prevent clinical remission and accelerate mucosal healing,
which will ultimately decrease the risk of worsening the symptoms and prevent
complicated surgical treatment for better life quality. The most commonly available
biologics include anti-tumor necrosis factor-alpha (TNF-a) agents knowns as infliximab,
adalimumab, certolizumab, and golimumab. Anti-integrin agents include vedolizumab
and natalizumab. Anti-interleukin 12-23 agent is ustekinumab. FDA-approved nonbiologic small molecule to treat moderate to severe UC is tofacitinib (M. Neurath, 2017).
Clinicians will choose among these therapeutic agents based on the phenotype of IBD,
behavior, drug exposure history, potential side effects, and patient co-morbidities.
Despite various drug availability, many of them show a loss of responses and severe
adverse effects
1.2.1 Immunosuppressive Drugs
Classic

immunosuppressive

drugs,

including

azathioprine

(AZA)

or

6-

mercaptopurine (6-MP), methotrexate (MTX), and ciclosporin-A (CSA), have been used
for induction or maintenance of remission in IBD patients. Overall supporting data show
that their efficacy is limited and contradictory, particularly in ulcerative colitis (Zenlea &
Peppercorn, 2014). 6-MP and AZA inhibit lymphocyte proliferation by incorporating
active drug metabolites into cellular nucleotides. This affects as anti-inflammatory
through suppression of T-cell function and natural killer (NK) cell activity. Doseindependent and hypersensitivity reactions of 6-MP/AZA have been reported to cause
hepatitis, pneumonitis, arthritis, and fever. The most serious health issue is pancreatitis,
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affecting about 4% of the treated patients. This can occur early stage of treatment and
usually clears up when medication is discontinued. Minor side effects such as nausea
and flu-like symptoms may be tolerated; however, some severe infections may be
accompanied by immunosuppression (Khan et al., 2011). In addition, a recent metaanalysis revealed that IBD patients treated with thiopurine have a four times higher
chance of developing lymphoma.
MTX is a folic acid antagonist, and it interrupts DNA synthesis and inhibits
interleukin-1 and T cell function. Its mode of action is less established compared to
thiopurines. There is evidence that MTX is somewhat effective in inducing and
maintaining remission of Crohn’s disease, but no convincing data is available for
ulcerative colitis. MTX is considered relatively safe and tolerable. Nausea can occur in
15% of treated patients, and adverse effects, including leukopenia, hepatoxicity,
hypersensitivity pneumonitis, and infection are reported (Chan & Cronstein, 2002).
CSA is a calcineurin inhibitor, and it functions to decrease pro-inflammatory
lymphokines by binding calcium calmodulin-dependent protein phosphatase calcineurin.
Available data shows that the use of calcineurin inhibitors in IBD is limited. It is proven
its use in the induction of remission of ulcerative colitis, but no convincing data is
provided that it is effective in the remission of Crohn’s disease. CSA is generally known
as less safe than other IBD drugs due to the high risk of anaphylaxis, seizure,
pneumocystis carinii pneumonia, and permanent nephrotoxicity (Bentin, 1995).
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1.2.2 Biologics
The introduction of TNF-alpha monoclonal antibodies and subsequent biologic
drugs may be the most significantly advanced therapeutics for IBD patients. Biologics
mainly include pro-inflammatory cytokine inhibitors and integrin antagonists.
Overexpression of TNF-alpha can induce chronic inflammation and cause
autoimmune diseases. Anti-TNF-alpha drugs, such as Infliximab (IFX) and Adalimumab
(ADA), have therapeutic effects by inhibiting TNF-alpha-mediated inflammatory
responses and tissue damage (Sandborn et al., 2009). IFX, a chimeric monoclonal
antibody that targets pro-inflammatory TNF-alpha, may be used to treat patients who do
not respond to CSS and immunomodulatory drugs (van Dullemen et al., 1995). IFX was
released in 1998 to treat moderate to severe CD, and this finding was replicated in a
more extensive placebo-controlled study where IFX can induce remission of 1/3 of
steroid-refractory CD patients. The study guided the current use of IFX as a therapeutic
agent to treat luminal CD showing results that 58% of patients were responsive
(Sandborn et al., 2012). IFX is also beneficial for UC treatment. IFX is considered safe
and effective but has the potential for serious complications. According to the clinical
trial, 32% of patients were found to have an infection, including one tuberculosis and
two deaths from sepsis. Development of lupus-like syndrome was rarely found as well
(Lichtenstein et al., 2006). ADA is a fully humanized recombinant monoclonal antibody
that is administered subcutaneously. In CD, results show that ADA has been effective in
inducing and maintaining remission in IFX-naïve moderate-to-severe patients. ADA also
helps to induce and maintain remission in moderate-to-severe UC patients who have

NEW THERAPEUTIC TO TREAT COLITIS

6

been obstinate to steroids, immunomodulators, or other anti-TNF-alphas (Sandborn et
al., 2007).
Anti-TNF therapeutics are not all-encompassing because up to 40% of IBD
patients do not respond to the inhibitors, and about 23-46% of patients experience lossof-response a year after the treatment (Ben-Horin, Kopylov, & Chowers, 2014). Dose
escalation and shorter interval injections may be helpful to achieve long-term remission,
but toxicity and safety may be the issue to consider.
1.2.3 Small Molecules
Janus kinase (JAK) family kinases JAK1, JAK2, JAK3, and tyrosine kinase 2
(TYK2) target multiple cytokine pathways, and JAK inhibitors block different signaling
pathways. Tofacitinib is orally administering small molecules that block all JAK1 and
JAK3 to treat severe UC patients. Clinical studies demonstrate that its onset is also fast
and effective in severe acute UC or refractory to anti-TNF-alpha; however, long-term
safety is not proven yet due to possible side effects such as infection and thrombosis
(Sandborn, Su, & Panes, 2017).
1.3 Hypothesis and Research Objectives
Chapter 1: PepT1-knockout (KO) mice harbor a protective metabolome beneficial
for intestinal wound healing
The objective of the chapter 1 study is to determine the anti-proinflammatory
effect of fecal metabolites derived from PepT1 KO mice using in vitro LPS-induced
inflammation model. Genetic knockout of PepT1 is known to provide resistance to acute
colitis and colitis-associated cancer (CAC) in mouse models. A recently published paper
demonstrated that PepT1 KO microbiota is sufficient to protect against colitis and CAC.
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Given that PepT1 KO alters the gut microbiome and thereby changes the intestinal
metabolites that are ultimately reflected in fecal samples, we hypothesized that selected
fecal metabolites show a direct anti-inflammatory effect and accelerated healing
process in vitro.
Chapter 2: Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the
injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis.
The objective of chapter 2 is to develop a novel therapeutic solution to orally
deliver lipid nanoparticles encapsulated IL-22 mRNA to downregulate pro-inflammatory
cytokines and increase the mucosal healing process in the UC mouse model. UC is
characterized by inflammation and ulceration of the colonic mucosa. Mucosal healing
offers a potential endpoint for UC treatment. Pre-resolving factors critical for colonic
epithelial restitution are downregulated during treatment with inhibitors of proinflammatory cytokines in UC. In this study, we hypothesized that an increased number
of factors, such as IL-22 in the inflamed mucosa, may increase the mucosal healing
process.
Chapter 3: Isolation, purification, and characterization of ginger-derived
nanoparticles (GDNPs) from ginger, Rhizome of Zingiber officinale
The objective of chapter 3 is to establish a precise and detailed protocol for
generating GDNPs, which can be used as a novel and non-toxic drug vehicle targeting
inflamed intestinal mucosa.
Chapter 4: Preparation and characterization of ginger lipid-derived nanoparticles
for colon-targeted siRNA delivery
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The objective of chapter 4 is to provide an accurate protocol showing the
synthesis of siRNA-loaded ginger-derived nanoparticles to create a siRNA/ginger-lipid
nano delivery system that can be used to treat colitis in dextran sodium sulfate (DSS)induced mouse model.

NEW THERAPEUTIC TO TREAT COLITIS

9

2 PEPT-1 KNOCKOUT MICE HARBOR A PROTECTIVE METABOLOME
BENEFICIAL FOR INTESTINAL WOUND HEALING
Copyright © 2021, Published by the American Physiological Society,
DOI.ORG/10.1152/ajpgi.00299.2020
2.1 Abstract
Genetic knockout (KO) of peptide transporter-1 (PepT1) protein is known to
provide resistance to acute colitis and colitis-associated cancer (CAC) in mouse
models. However, it was unclear which molecule(s) or pathway(s) formed the basis for
these protective effects. Recently, we demonstrated that the PepT1-/- microbiota is
sufficient to protect against colitis and CAC. Given that PepT1 KO alters the gut
microbiome and thereby changes the intestinal metabolites that are ultimately reflected
in the feces, we investigated the fecal metabolites of our PepT1 KO mice. Using a liquid
chromatography-mass spectrometry (LC-MS)-based untargeted-metabolomics
technique, we found that the fecal metabolites were significantly different between the
KO and normal wild-type (WT) mice. Among the altered fecal metabolites, tuberonic
acid (TA) was seven-fold higher in KO mouse feces than WT mouse feces. Accordingly,
we studied whether the increased TA could direct an anti-inflammatory effect. Using in
vitro models, we discovered that TA both prevented lipopolysaccharide (LPS)-induced
inflammation in macrophages and improved epithelial cell healing processes. Our
results suggest that TA, and possibly other fecal metabolites, play a crucial role in the
pathway(s) associated with the anti-colitis effects of PepT1 KO.
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2.2 Introduction
Peptide transporter 1 (PepT1) is a proton oligopeptide transporter that plays a
critical role in transporting di/tripeptides and maintaining intestinal homeostasis
(Charrier & Merlin, 2006). PepT1 is typically expressed in the small intestinal epithelial
cells, whereas it is not detected in colonic epithelial cells (Wuensch et al., 2013;
Zucchelli et al., 2009). Accumulated evidence suggests that over-expression of PepT1
in the colon is associated with the pathogenesis of inflammatory bowel disease (IBD),
which is a chronic inflammatory disorder of the gastrointestinal (GI) tract that affects
more than three million people in the US (Dalmasso et al., 2008; P. Wang et al., 2013).
IBD includes two dominant clinical phenotypes: ulcerative colitis (UC) and Crohn's
disease (CD) (Molodecky et al., 2012). Both UC and CD patients were found to exhibit
high-level expression of PepT1 in their colons (Zucchelli et al., 2009), suggesting that
targeting PepT1 might be a useful therapeutic approach for the treatment of IBD.
Studies performed using the recently established PepT1-knockout (KO) mouse
model (PepT1-/-) have further shown that PepT1 plays a central role in the etiology of
IBD (Miyake, Fujishima, & Nakai, 2017; Zucchelli et al., 2009). Notably, the genetically
modified PepT1-KO mouse presents with resistance to dextran sulfate sodium (DSS)induced acute colitis (Dai et al., 2015; Zucchelli et al., 2009). Our group and others have
demonstrated that the lack of intestinal PepT1 expression reshapes the gut microbiota
and that this contributes to preventing colitis and colitis-associated cancer (CAC)
(Viennois et al., 2020; Yuri et al., 2020). Specifically, KO of PepT1 modified the
intestinal bacterial ratio of Firmicutes to Bacteroidetes (F/B) (Viennois et al., 2020). This
change of F/B ratio has been repeatedly associated with an altered metabolic profile of
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the host, which might change the risks for triggering several diseases, such as
metabolic symptoms, obesity, and cancer (Cani & Delzenne, 2011; Chassaing, EtienneMesmin, & Gewirtz, 2014; Louis, Hold, & Flint, 2014; Sharon et al., 2014). Therefore, we
hypothesized that the metabolic profile of feces from PepT1-KO mice would be
significantly affected by the altered microbiota and that the altered fecal metabolites
might play a critical role in the anti-inflammatory effects of PepT1 KO in mice. To test
our hypothesis, we analyzed the composition of fecal metabolites from KO and WT mice
by

LC-MS-based

metabolomics

and

tentatively

identified

significantly

altered

metabolites (Figure 1). We then tested the in vitro anti-inflammatory and wound-healing
effects of one significantly upregulated fecal metabolite. Such a strategy could offer a
unique approach for identifying potential anti-inflammatory metabolites for the treatment.
2.3 Materials and Methods
2.3.1 Chemicals
Tuberonic acid (TA) was purchased from Toronto Research Chemicals (North
York, ON, CA). 6-shogaol was purchased from Sigma-Aldrich (St. Louis, MO).
Potassium chlorate (KCl), methanol, dichloromethane, and LC-MS grade acetonitrile
were purchased from Sigma-Aldrich (St. Louis, MO). Formic acid (98%, LC-MS grade)
and phosphate buffer saline (PBS, Corning Life Sciences, Tewksbury, MA) were
obtained from Fisher Scientific (Hampton, NH). Fetal bovine serum (FBS) was obtained
from R&D Systems (Flowery Branch, GA). Ultrapure deionized water was supplied by a
Millipore Milli-Q water system (Bedford, MA).
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2.3.2 Fecal Metabolite Extraction
WT (PepT1+/+) mice (C57BL/6, female, 7-8 weeks old) were purchased from
Jackson Laboratory (Bar Harbor, ME). PepT1-KO mice (PepT1-/-, C57BL/6, female, 7-8
weeks old) were bred by the reported method (Viennois et al., 2019; Viennois et al.,
2020). Feces from individual mice were collected and freeze-dried by a lyophilizer
(Labconco, Kansas City, MO). In general, 50 mg of dried feces were used to extract the
whole metabolites by adding 800 µL 80% icy cold methanol. After 30 min of sonication
(in an ice bath), all samples were incubated at -20°C for 1 hr. The samples were then
vortexed for ~2 min and centrifuged at 12,000 rpm at 4°C for 10 min. The supernatant of
extraction was then lyophilized and reconstituted in 15 µL of 50% methanol, filtered
through 0.22 µm filter, and transferred to 2.0 mL HPLC injection vials. Quality control
(QC) sample was made by mixing 6 different samples, and LC retention times of QC
samples were used to evaluate the stability of the LC-MS system.
2.3.3 Ultra-High-Performance Liquid Chromatography Time-of-Flight Mass
Spectrometry (UPLC-TOF-MS)
High-resolution accurate mass spectrometry (HRMS) data were acquired by
UPLC-TOF-MS, equipped with Ultimate-3000 LC and Q-Exactive MS (Thermo Fisher
Scientific, Waltham, MA). The acquisition was performed with ESI-MS in non-targeted
MS/MS mode. The UPLC system contained a Thermo Hyper gold C18 (100 x 2.1mm 1.9
µm) column for the peak separation. The mobile phase was composed of solvent A
(0.1% formic acid, 5% acetonitrile, and 94.9% water) and solvent B (0.1% formic acid99.9% acetonitrile) and was run in a gradient elution mode. The flow rate of the UPLC
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was set as 0.3 mL per min, and the temperature of the column was kept at 40°C. The
sample injection module was kept at 4°C all the time.
2.3.4 Identification of Metabolites
Acquired UPLC-HRMS data were converted to *.mzXML format by open-source
software (ProteoWizard, Version: 3.0.18320, Palo Alto, CA) and uploaded to the XCMS
website (https://xcmsonline.scripps.edu). The uploaded HRMS data from two groups of
mouse fecal metabolites (KO and WT) were matched via Metlin online metabolomics
database (https://metlin.scripps.edu), which contains over a million molecules ranging
from lipids, steroids, plant & bacteria metabolites, small peptides, carbohydrates,
exogenous drugs/metabolites, central carbon metabolites, and toxicants. The searching
used a positive charged mass feature, including [M+H]+, [M+Na]+, [M-H2O+H]+, and [MH2O+Na]+, and with an M/z accuracy no more than 3.0 ppm.
2.3.5 Cell Culture for In Vitro Anti-Inflammatory Assay
Mouse macrophage cells (RAW 264.7, ATCC, Manassas, VA) were used to test
the selected metabolites' in vitro anti-inflammatory effects. The passage number of the
macrophage cells was between 3 and 5. Approximately 1.0 x 105 macrophage cells
were seeded in 6 well plates (Corning Life Sciences, Tewksbury, MA) and cultured with
2 mL of Dulbecco's Modified Eagle Medium (DMEM, Corning Life Sciences, Tewksbury,
MA) containing 10% fetal bovine serum (FBS, R&D systems, Flowery Branch, GA).
After the cell reached ~75% of confluence (judged by the percentage of the plate bottom
area covered with cells), the culture medium was replaced by a new DMEM medium
(with 10% FBS) with or without tuberonic acid and incubated for another 12 h. 6-shogaol
containing DMEM (with 10% FBS) was used as the positive control. After the treatment,
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the culture medium was removed, and cells were activated by adding diluted LPS in the
medium (200 ng/mL of LPS, without FBS) and incubate for another 4 h at 37°C.
2.3.6 Cytokine mRNA Expression Level
Total RNA was extracted and purified from RAW 264.7 cells by RNeasy Mini Kit
(Qiagen, Hilden, DE). RNA extracted from the samples was used to generate
complementary DNA (cDNA) with Maxima cDNA Synthesis Kit (Thermo Scientific,
Waltham, MA). Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific,
Waltham, MA) was used to analyze the RNA expression of pro-inflammatory cytokines
(including TNF-α, IL-1β, and IL-6) and anti-inflammatory cytokines (such as IL-10 and
IL-22). Results were normalized with 36B4, the housekeeping gene. Following sense
and anti-sense primers were used: TNF-α: 5’-AGGCTGCCCCGACTACGT-3' and 5’GACTTTCTCCTGGTATGAGATAGCAAA-3'; IL-1β: 5’-TTGACGGACCCCAAAAGATG3'

and

5’-AGAAGGTGCTCATGTCCTCAT-3';

IL-6:

5’-ACAAGTCGGAGGCT

TAATTACACAT-3' and 5’-TTGCCATTGCACAACTCTTTTC-3'; IL-10: 5’-GGTTGCCA
AGCCTTATCGGA-3'

and

5’-CTTCTCACCCAGGGAATTCA-3';

IL-22:

5’-

GTCAACCGCACCTTTATGCT-3' and 5’-GTTGAGCACCTGCTTCATCA-3'; and 36B4:
5’-TCCAGGCTTTGGGCATCA-3' and 5’-CTTTATCAGCTGCA CATCACTCAGA-3'. RT2
Profiler PCR array (Qiagen, Hilden, Germany) was used to investigate cytokines' mRNA
level in the toll-like receptor signaling pathway. A full list of investigated genes can be
found on Qiagen's gene globe website (https://geneglobe.qiagen.com/us/productgroups/rt2-profiler-pcr-arrays).

The procedures, including constructing cDNA and

qPCR, were implemented by the manufacturer's instruction.
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2.3.7 Extracellular Cytokine Levels
Mouse cytokine array panel A kit (protein profiler, R&D Systems, Minneapolis,
MN) was employed to evaluate the cell culture medium's extracellular cytokine levels.
For each sample, a 1.0 mL cell culture medium was mixed with 0.5 mL testing buffer
and incubated with the cytokine array membrane. Bio-Rad ChemiDoc XRS+ System
exposed the protein profiler membranes; the system was set at gel imaging for blots, at
Chemi Hi-Resolution condition, and with an exposure time of 75 s. The cytokine array
blotting pictures was quantitively analyzed by Image Studio software (Li-cor, Lincoln,
NE). The intensity values of different dots (proteins) were exported in an excel format
and visualized by Prism 8 (GraphPad, San Diego, CA).
2.3.8 Statistical Analysis
One-way and two-way analyses of variance (ANOVA) and t-tests were used to
determine statistical significance (*P < 0.05, **P < 0.01, ***P < 0.001). Principal
component analysis (PCA) and cluster analysis were performed through the XCMS
online

cloud

computing

functions

(https://xcmsonline.scripps.edu).

Heat

map

visualization of upregulated and downregulated metabolites was processed by Prism 8
(GraphPad, San Diego, CA).
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Figure 1. Flowchart of metabolite analysis of fecal samples from WT and PepT1KO mice.
2.4 Results
2.4.1 KO of PepT1 Protein Alters the Fecal Metabolite Profiles of Mice
Fecal metabolites, such as phenolics, indoles, carbohydrates, and short-chain
fatty acids, regulate gut homeostasis and provide a functional readout of gut microbial
activity. A shift of the fecal metabolite profile often reflects an alteration of the digestive
system's genetic or epigenetic factors and thus has diagnostic and/or prognostic value.
Using UPLC-HRMS-based metabolomic technology, we obtained high-resolution LCMS data on the metabolites found in KO and WT mice's feces. We then compared their
fecal metabolite profiles. As shown in Figure 2A, a total of 1176 fecal metabolites were
altered under PepT1 KO; approximately two-thirds were upregulated (green dots in
Figure 2A), and one-third was downregulated (red dots in Figure 2A). Principal
component analysis (PCA) demonstrated the presence of clear edges between the KO
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and WT groups, confirming that these groups could be easily discriminated by their
respective fecal metabolite profiles (Figure 2B). Further, 83 (out of 1176) metabolites
were significantly altered with a fold change larger than 7 (Figure 2C). Interestingly, a
heatmap (Figure 2D) of these 83 significantly altered metabolites showed that one (at
LC-MS/MS retention time 3.38 min) was significantly upregulated (Figure 2D and 3A).

NEW THERAPEUTIC TO TREAT COLITIS

18

Figure 2 Knockout PepT1 alters the metabolomics profiles in feces. A)
Upregulated and downregulated metabolites in feces (PepT1-/-[KO] versus
PepT1+/+[WT]), B) PCA analysis of KO versus WT fecal metabolites, C) Altered
metabolites with significant fold change (>7), and D) Heat map of metabolites
with significant fold change (>7) (n=5).
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2.4.2 TA was Significantly Upregulated in the KO Mouse Group
Multiple-stage HRMS-based metabolomic techniques allow researchers to
putatively identify metabolites via multiple aspects, including the parent ion (MS1),
product ions (MS2), fragmentation pattern, and established databases. We used these
high-resolution LC-MS/MS features to tentatively identify the peak at retention time 3.38
min. The MS1 data (ESI+) showed that the pseudo molecular weight of this peak was
227.1278 [M+H]+ (Figure 2B); this suggested a molecular formula of C12H18O4, which
was consistent with that of 12-hydroxy jasmonate (also known as tuberonic acid [TA]).
When we analyzed the MS2 spectrum of this compound, the MS2 bar graphs at
209.1172, 191.1065, 163.1117 showed the fragment ions of [M-H2O+H]+, [M-2H2O+H]+,
and [M-2H2O-CO+H]+ (Figure 2B), indicating that the fragment moieties of this
compound were C12H16O3, C12H14O2, and C11H14O, respectively. Such a fragmentation
pattern was consistent with that of TA. We thus concluded that this peak corresponded
to TA.
2.4.3 Upregulated Colonic Metabolite TA has an In Vitro Anti-Inflammatory Effect
To confirm the selected upregulated fecal metabolite's anti-inflammatory effects,
we tested whether TA could prevent the LPS-induced inflammation in macrophages.
RAW 264.7 macrophages were incubated with culture medium containing three different
concentrations of TA (1, 2, or 4 µg/mL) and 10% FBS. After 4 h, the TA-containing
medium was replaced with serum-free medium, and LPS (final concentration, 200
ng/mL) was spiked to activate the macrophages. LPS is known to activate the
transcription of inflammatory mediators and cytokines. As shown in Figure 3, TA
treatment significantly decreased the levels of pro-inflammatory cytokines (TNF-α, IL-6,
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and IL-1β) and increased those of the anti-inflammatory cytokine, IL-22. However, TA
treatment did not appear to affect the mRNA expression of IL-10. These results indicate
that TA has an anti-inflammatory effect against LPS-induced inflammation and that this
effect may not include the IL-10-dependent pathways. As a ligand of toll-like receptor
(TLR), LPS typically evokes macrophage polarization via LPS/TLR4 signal transduction
pathway toward a classically activated macrophage (M1) (Kalish et al., 2015;
Orecchioni, Ghosheh, Pramod, & Ley, 2019). Delayed or untimely treatment of M1
macrophage-induced inflammatory response can disturb normal tissue homeostasis
and hamper vascular repair (Wynn & Vannella, 2016). Thus, we further investigated
whether TA-treatment could affect LPS/TLR4 signal transduction to gain more
mechanistic insight into TA's anti-inflammatory effects. Using a TLR signaling pathway
PCR array, we investigated 84 TLR pathway-focused mRNAs, including genes related
to TLRs, pathogen-specific responses, TLR signaling, signaling downstream TLRs,
regulation of adaptive immunity, TLR interacting proteins & adaptors, and downstream
effectors of TLR signaling. We found that TA treatment remarkably reduced the mRNA
level of TLR-4, C-C Motif Chemokine Ligand 2 (CCL2), CD80, and IL-6, indicating that
TA interferes with the LPS/TLR4 signaling pathway and may prevent LPS-induced
macrophage polarization towards pro-inflammatory M1-like phenotype (Bertani et al.,
2017; Ruytinx, Proost, Van Damme, & Struyf, 2018; Trombetta et al., 2018). The
downregulation of IL-6 expression was also proved by a protein profile screening test for
the extracellular cytokines.
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Figure 3. In vitro anti-inflammatory assay. A) Gene expression fold changes of
TNF-, B) IL-1β, C) IL-6, D) IL-10, and E) IL-22 in inflamed RAW 264.7 cells treated
with control (medium), LPS, or LPS+TA (2 or 4 µg/mL). (*P < 0.05, **P < 0.01, ***P <
0.001, n=3)
2.4.4 TA Promotes Wound Healing In Vitro
Enhancement of wound healing in the mucosal layer has been shown to have a
synergic effect with anti-inflammatory treatment; therefore, agents that can promote
wound healing favor UC patients' recovery. Here, we used the electric cell-substrate
impedance sensing (ECIS) method to study TA's effect on the epithelial wound-healing
capability in vitro. The ECIS instrument measures AC impedance using weak and
noninvasive AC signals, as previously described (Keese, Wegener, Walker, & Giaever,
2004). The attachment and spreading of cells on the electrode surface change the
impedance so that morphological information of the attached cells can be inferred. The
measurement system consists of an 8-well culture dish, with the well's surfaces treated
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for cell culture. There is a small active electrode (area = 5 x 10–4 cm2) and a large
counter electrode (area = 0.15 cm2) on the bottom of each well. A lock-in amplifier with
an internal oscillator is used to switch among the different wells, and a computer is used
to take measurements and store the data. In previous experiments, we determined the
ideal frequency for measuring the resistance of confluent Caco-2BBE monolayers
(Merlin-Zhang, Sung, & Viennois, 2019). We measured the resistance during a
frequency scan of cells plated on ECIS 8W1E plates and measured the resistance
during a frequency scan of a naked electrode from which the cells had been removed
by trypsinization. The log (resistance) ratio with cells versus without cells was
calculated, and the ideal frequency was taken as the frequency with the maximum ratio.
For resistance measurements performed on Caco2-BBE cells, the frequency used was
500 Hz, and the voltage was 1 V (Charrier et al., 2005). For the wound-healing assays,
Caco2-BBE cells cultured to confluence on ECIS 8W1E plates were subjected to a
voltage pulse of 40 kHz frequency, 4.5-V amplitude, and 30-second duration. This
process kills the cells around the small active electrode, causing detachment and
generating a normally healable wound by surrounding cells that have not been affected
by the voltage pulse. Continuous resistance was then continuously measured to
assessed wound healing for approximately 30 h after the wound. As shown in Figure 4,
the epithelial layer of wounded cells treated with TA showed significantly accelerated
recovery compared to those of the blank (medium) groups and negative control (1%
Triton) during the period of incubation (approximately 43-57 h). The TA-treated group's
initial acceleration rate was similar to that of the positive control (6-shogaol). These
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results suggest that TA enhances the healing of wounded epithelium in an in vitro
model.

Figure 4. Representative cell growth curves (as indicated by electrical
resistances) in an in vitro wound-healing assay of TA. Confluent Caco2-BBE
cells seeded to ECIS plates were wounded using an elevated voltage pulse of
40 kHz frequency, 4.5 V amplitude, and 30-s duration. After the wounding, TA
(4.0 µg/mL), 6-shogaol (1.0 µg/mL), culture medium (blue), or Trizol (purple, 1%
in medium) were added to the wounded Caco2-BBE cell monolayers. The
wounded Caco2-BBE cell monolayers were then allowed to heal (presumably
from cells that did not undergo the elevated voltage pulse and surround the
small active electrode). Resistance was measured before and after applying
the elevated voltage pulse, as described in the Materials and methods section
(n=3).
2.5 Discussion and Future Direction
Previous studies have demonstrated that gut microbiota from PepT1-KO mice
exhibited anti-colitic and anti-CAC effects (Viennois et al., 2020). As the colonic
mucosal barrier protects the colonic epithelial cells and segregates the microbiota,
these effects are probably derived from the effects of mucosal-penetrable molecules,
such as small-molecule metabolites (Matsumoto & Benno, 2006; Storr, Vogel, &
Schicho, 2013). Fecal metabolites, most of which are small molecules derived from the
digestive system, reflect the gut microbiota's metabolic profile and mirror the host's
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genetic and epigenetic characteristics (Druart et al., 2014; Walker et al., 2014). Here,
we used LC-MS-based metabolomics techniques to test and confirm our hypothesis that
KO of PepT1 affects the downstream fecal metabolic profile. Systematic identification of
small-molecule metabolites, also known as untargeted metabolomics, is a challenging
task and often requires sophisticated analytical instruments, such as LC-MS, gas
chromatography (GC)-MS, and nuclear magnetic resonance (NMR) (Coene et al., 2018;
Huang et al., 2018). MS- and NMR-based metabolomics each have advantages and
limitations and are often used simultaneously to obtain complementary data on the
metabolites (Hamerly et al., 2015; Li et al., 2019; Yanshole et al., 2014). Given the rapid
advances of modern mass spectrometers (especially the Orbitrap and time-of-flight
[TOF] instruments) and the richness of the established HRMS metabolomics database,
the putative identification of metabolites solely by MS-based metabolomics is more
accessible now than ever before (Li et al., 2019; Liu et al., 2019). Using modern LCHRMS-based technology, we herein found that the metabolite, TA, was remarkably
upregulated in PepT1 KO mice's fecal samples. This suggests that LC-HRMS-based
metabolomics could be a feasible strategy for identifying significantly altered smallmolecule metabolites after upstream gene modification.

As mentioned above, we

recently demonstrated that PepT1 expression affects host mucosal homeostasis and
shapes the microbiota (Viennois et al., 2020). We also know that β-glycosidase
activities present in the colonic microbiota act on glycosidic plant secondary compounds
and xenobiotics entering the colon and may have health implications for the host (Byun
et al., 2015). Information on β-glycosidase activity is currently limited to relatively few
bacteria species in the colonic ecosystem (Dabek, McCrae, Stevens, Duncan, & Louis,
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2008). In this context, TA could arise from tuberonic acid glucoside (TAG), a compound
widely found in foods (Seto et al., 2011; Seto et al., 2009; Wakuta et al., 2010). Some
bacteria found in PepT1-/- mice but not in WT mice may have β-glucosidase and able to
cleave the TAG to TA and glucose. This might cause a high tuberonic acid (TA) level in
PepT1-/- feces compared to WT feces. Given that food is a major source of precursors
for metabolite production, our next study will investigate which bacteria in PepT1 -/microbiota could metabolize food TAG via the β-glucosidase-mediated cleavage.
Chemically, TA is a jasmonate classified among the plant stress hormones and plant
metabolites (Koo & Howe, 2009; Umukoro, Akinyinka, & Aladeokin, 2011). Intriguingly,
methyl-jasmonate, an analog of TA, was found to inhibit LPS-induced inflammatory
cytokine production in macrophages (RAW 264.7 cells) and reduce oxidation stress in
the liver and brain of arthritic rats (Gunjegaonkar & Shanmugarajan, 2019; PereiraMarostica et al., 2019; Sa-Nakanishi et al., 2018; L. Zhang & Xing, 2008). These reports
suggested that jasmonate analogs might be potent anti-inflammatory lead compounds.
Our current in vitro study of TA supports this notion. We found that TA inhibited the
expression of pro-inflammatory cytokines (TNF-, IL-1β, and IL-6) and promoted the
expression

of

an

anti-inflammatory

cytokine

(IL-22)

in

LPS-induced inflamed

macrophages. We speculate that the generated TA in the intestinal lumen could be
taken up by intestinal epithelial cells, and this could increase the mucosal healing
process during colitis. Other cell types, such as inflamed macrophages, may also take
up TA, which could decrease pro-inflammatory cytokines' secretion (TNF-a, IL-1β, and
IL-6) increase an anti-inflammatory cytokine (IL-22) from inflamed macrophages during
colitis. Tissue culture-based wound-healing assays have been used for many years to

NEW THERAPEUTIC TO TREAT COLITIS

26

estimate different cells' migration and proliferation rates under various culture
conditions. These assays involve using instruments such as razor blades to "wound" a
confluent monolayer of cells. The open wound is then microscopically monitored over
time as the cells undergo restitution. This "healing" process can take several hours to
more than a day, depending on the cell type, culture conditions, and the wound's extent.
The results are often presented as a series of photomicrographs and quantified via
ocular micrometer-based measurements of the gap size over time. These assays' main
disadvantages include a lack of reproducibility and an inability to quantify wound healing
precisely (Xiao et al., 2017). Here, we investigated tuberonic acid's effect on wound
healing in vitro using ECIS (electric cell-substrate impedance sensing) technology. As
expected, TA exhibited excellent wound-healing efficacy on colonic epithelial cells in the
ECIS assay. Given these encouraging results, our future work will seek to test TA's in
vivo anti-inflammatory efficacy in acute or chronic colitis animal models.
The present study is not without limitations. First, fecal metabolites comprise a
mixture of metabolites produced by both the gut microbiota and the host, so it is not yet
clear whether the observed upregulation of TA is a direct effect of PepT1 KO or a
consequent result of the altered gut microbial metabolism. Second, TA is a compound
of mixed enantiomers (Nonaka, Ogawa, Maeda, Wang, & Kobayashi, 2010; Seto et al.,
2011), meaning that future research will be needed to isolate and reveal TA's most
effective stereoisomer. Moreover, future drug dose and formulation studies are needed
to optimize TA's use to treat colitis and CAC. This study provides proof of principle for
the idea that specific fecal metabolites from PepT1 may have anti-inflammatory
activities. Further studies will be necessary to characterize other anti-inflammatory fecal
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metabolites from PepT1 KO mice to use them to find therapeutic solutions for treating
colitis.
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3 ORAL DELIVERY OF IL-22 MRNA-LOADED LIPID NANOPARTICLES TARGETING
THE INJURED INTESTINAL MUCOSA: A NOVEL THERAPEUTIC SOLUTION TO
TREAT ULCERATIVE COLITIS
Copyright © 2022, Published by the Biomaterials,
DOI.ORG/10.1016/j.biomaterials.2022.121707
3.1 Abstract
Oral mRNA delivery is a promising yet understudied approach for treating
inflammatory bowel disease (IBD). Inspired by the colon-targeting ability of gingerderived nanoparticles (GDNPs), we reversely engineered lipid nanoparticles that
comprise the three major lipids identified in GDNPs. When mixed at the ratio found in
GDNPs, the selected lipids (phosphatidic acid, monogalactosyldiacylglycerol, and
digalactosyldiacylglycerol; 5:2:3) self-assembled into new lipid nanoparticles (nLNPs) in
phosphate-buffered saline. We encapsulated IL-22-mRNA within the nLNPs, as
enhanced IL-22 expression in the colon is known to have potent anti-inflammatory
efficacy against ulcerative colitis (UC). The IL-22 mRNA-loaded nLNPs (IL-22/nLNPs)
were found to be about 200 nm in diameter and have a zeta potential of -18 mV. Oral
delivery of IL-22/nLNPs elevated the protein expression level of IL-22 in the colonic
mucosa of mice. In a mouse model of acute colitis, mice fed with IL-22/nLNPs
experienced an accelerated healing process, as indicated by the recovery of more body
weight and colon length as well as reduction of the histological index, colonic MPO
activity, fecal lipocalin concentration, and mRNA expression levels of pro-inflammatory
cytokines (TNF-α, IL-6, and IL-1β). Our results suggest that our reversely engineered
nLNP is an excellent mRNA delivery platform for treating ulcerative colitis.
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3.2 Introduction
Inflammatory bowel disease (IBD), an umbrella term for Crohn’s disease (CD)
and ulcerative colitis (UC), is a relapsing and chronic inflammatory disorder of the
gastrointestinal (GI) tract that affects more than 3 million adults in the US (Alatab et al.,
2020). The etiology of the disease is still unclear, and there appear to be several nonspecific pathophysiological causes, making it challenging to develop effective diagnostic
and therapeutic strategies for IBD (Fiocchi, 2015; Xavier & Podolsky, 2007; Y. Z. Zhang
& Li, 2014). Recent scientific research has yielded several IBD therapeutics, including
biologics (e.g., anti-tumor necrosis factor-alpha, anti-interleukin, and anti-integrin),
antibiotics, corticosteroids, and immunomodulators. Unfortunately, most of these
treatments are delivered systemically and thus cause severe short- or long-term side
effects, such as affecting gut bacterial/fungal function and promoting cancer
development (Neurath, 2017).
Interleukin-22 (IL-22), a member of the IL-10 cytokine family, is a well-known
regulator of epithelial homeostasis. Unique biological properties enable IL-22 to promote
wound healing during intestinal inflammation. Moreover, IL-22 plays a protective role
against pro-inflammatory mediators and is strongly associated with IBD susceptibility
genes, such as jak1, tyk2, and STAT3 (Sugimoto et al., 2008). The local microinjection
of a lipid/IL-22 cDNA vector complex was shown to activate innate immune pathways in
a mouse model of Th2-mediated colitis that closely mimics human UC. Local IL-22
cDNA delivery enhanced STAT3 activation in colonic epithelial cells, induced STAT3dependent expression of mucus-associated molecules, and promoted restitution of
goblet cells. Notably, IL-22 cDNA delivery ameliorated local intestinal inflammation,
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likely via enhanced mucus production. Inhibition of IL-22 activity via overexpression of
IL-22–binding protein suppressed goblet cell restitution in the recovery phase of a
dextran sulfate sodium (DSS)–induced mouse model of acute colitis. These data
collectively indicate that local microinjection of a lipid/IL-22 cDNA vector complex is
potentially a powerful strategy for treating colitis in the experimental animal model.
Although microinjection is effective, its clinical application has been hampered by
the general requirement for surgery and specific injection skills. In contrast, oral delivery
offers a more accessible treatment strategy that is conducive to patient compliance.
From this aspect, developing an oral gene delivery method for IBD treatment appears to
have more translational value than microinjection. We previously showed that orally
delivered a subgroup of ginger-derived nanoparticles (GDNPs) targeted the colon (M.
Zhang et al., 2016) and potently delivered CD-98 siRNA (M. Zhang, Wang, Han, Collins,
& Merlin, 2017) and small molecule drug candidate 6-shogaol to treat UC (C. Yang,
Long, Sung, Alghoul, & Merlin, 2021; L. Yang, Yang, Teng, & Katayama, 2020). We
also discovered that three types of lipids contribute more than 90% of the total lipids in
the

subgroup

of

GDNPs.

These

three

lipids

are

phosphatidic

acid

(PA),

monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG) (M.
Zhang et al., 2016; M. Zhang et al., 2017). We hypothesized that mixing these three
lipids at the ratio found in the subgroup of GDNPs would enable us to form
nanoparticles that would retain the nanostructure of GDNPs and might prove useful as a
well-defined nano-gene delivery system.
Here, we tested these hypotheses. We found that a film hydration method similar
to that used to make liposomal nanoparticles could be applied to self-organize a lipid
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mixture containing PA, MGDG, and DGDG into new lipid nanoparticles (nLNPs) with
properties nearly identical to those of GDNPs (e.g., size, zeta potential, and spherical
shape). We then investigated the efficacy of oral delivery of IL-22 mRNA-loaded nLNPs
as a novel therapeutic strategy for treating UC.
3.3 Materials and Methods
3.3.1 Synthesis of IL-22 mRNA In Vitro Transcription (IVT)
The full-length IL-22 mRNA (Gene ID: 50929) was designed with an ampicillinresistant lentiviral vector pMRNAxp backbone, which encodes T7 promoter, 5’UTR,
3’UTR, a polyA tail, and pUC origin (System Bioscience, Palo Alto, CA). With the
constructed IL-22 plasmid DNA, in vitro transcription (IVT) method was used to
synthesize IL-22 mRNA using the mRNAExpressTM mRNA synthesis kit (System
Biosciences, Palo Alto, CA). The cloning mixture containing NTP/Cap mix, reaction
buffer, T7 RNA poly mix, nuclease-free water, and template IL-22 plasmid DNA was
incubated at 42°C in the water bath for 2 hrs. Then, the mixture was incubated at 37°C
for 30 min after DNase and phosphatase treatment. DNase was used to digest the DNA
template after mRNA synthesis, and phosphatase was used to remove 5’ triphosphates
in the final stage of RNA synthesis. Next, newly generated mRNAs were purified by
centrifugation with the addition of elution buffer, binding buffer, and 100% ethanol
following the manufacturer’s instruction (System Biosciences, Cat# MR-KIT-1, ver. 2070918).
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3.3.2 Preparation and Encapsulation of IL-22 mRNA with Raw Lipid Nanoparticles
(rLNPs)
Raw lipids were extracted from ginger-derived nanoparticles (GDNPs) by the
liquid-liquid extraction method (Sung, Yang, Viennois, Zhang, & Merlin, 2019). After
extraction, the upper aqueous phase was removed, and the remaining lower organic
phase was dried under vacuum to obtain the raw lipids. Raw lipids were weighed and
stored under -20°C for further use. To make IL-22 mRNA rLNPs formulation, we
prepared IL-22 mRNA solution in RNase-free water (containing 5% glucose), then,
Turbofect (Thermo Fisher Scientific, Waltham, MA) was added mixture was incubated at
room temperature for 15 mins. The mixed solution was transferred to a pear-shaped
flask with lipid thin film prepared from the raw lipids, and the flask was sonicated with
repeated pipetting. Lipid vesicles encapsulated the IL-22 mRNA complex by thin-film
hydration. Before the in vivo use, raw lipid nanoparticles (rLNPs) were measured in size
and loading efficiency. The detailed procedure can be retrieved from previously
published bio-protocol (Sung, Yang, Collins, & Merlin, 2020).
3.3.3 Preparation of New Lipid Nanoparticles
Digalactosyldiacylglycerol (DGDG), Monogalactosyldiacylglycerol (MGDG), and
phosphatidic acid (PA) were purchased from Avanti polar lipids (Alabaster, AL). We
dissolved three lipids with dichloromethane (DCM) in glass tubes and mixed them in a
ratio of 3:2:5, which mimics the lipid composition discovered in the subgroup of naturally
occurring GDNPs. Thin-layer chromatography (TLC) was used to demonstrate the lipid
profiles from nLNPs and the GDNPs. DGDG, MGDG, and PA standards were also
spotted on the TLC plate as references. After spotting the samples, the TLC plate (silica
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gel, sigma-Aldrich) was developed in a glass chamber with a mobile phase composed
of DCM (80%) and Methanol (20%) and visualized by exposing the developed TLC
plate to iodine (I2) vapor. To prepare the nLNPs, we transferred the DGDG, MGDG, and
PA mixture to a pear-shaped flask and submitted it to a vacuum Rota-vapor to establish
the lipid thin film. The mRNA encapsulation step was identical as described in section
2.2.
3.3.4 Measurement of Particle Size, Zeta Potential, Topographical Morphology,
and Loading Efficiency
Lipid nanoparticles were suspended in phosphate-buffered saline (PBS) at a
concentration of between 10-100 µg/mL to measure particle size and surface zeta
potential. Particle sizes (nm) and zeta potential (mV) of NPs were measured by dynamic
light scattering (DLS) using Zetasizer (Malvern Panalytical, Westborough, MA). The
average and standard deviations of the diameters (nm) or zeta potential (mV) were
calculated using three runs. Each run is an average of 10 measurements. The
morphological image was acquired by CoreAFM atomic force microscopy (Nanosurf,
Liestel, Switzerland). The detailed procedure can be found in the published bio-protocol
paper (Long, Yang, Sung, & Merlin, 2021). Scanning electron microscopy (SEM)
images were acquired by Tescan Vega3/EDEX (Tescan Analytics, Fuveau, France).
The loading efficiency (LE) of IL-22 mRNA to nLNPs was tested using the
ultracentrifugation method. IL-22/nLNPs (A) or free IL-22 mRNA (B) (at the same
concentration) was suspended in 5% glucose with a final concentration of ~50 µg/mL
(calculated by mRNA) and centrifuged using ultracentrifuge Allegra X-15R with TLA 55
rotor (Beckman Coulter, Brea, CA) at 30,000 rpm (55,300 x g) and 4°C for 10 min. The
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supernatants of A and B were quantitated for mRNA concentrations using a BioTek
Synergy 2 plate reader (Agilent, Santa Clara, CA, USA) with an RNA reading plate at
UV wavelength 260/280 nm. The LE is calculated by ([absorption of B ─ absorption of
A]/absorption of B)x100%.
3.3.5 In Vitro Stability and In Vivo Biodistribution
The stability of IL-22/nLNPs was characterized by agarose gel electrophoresis.
10 µL of each sample, including IL-22 mRNA and IL-22/nLNPs, were loaded into wells
of 2% agarose gel with GelRed (Biotium, Fremont, CA) added. Electrophoresis was
conducted at 100 V for 45 min in 1x Tris/acetic acid/EDTA buffer (TAE, pH 8) (Biorad,
Hercules, CA). The naked IL-22 mRNA and nLNPs-encapsulated IL-22 mRNA was
exposed to 4 µL of RNase (0.04 mg/mL) at 37°C for 0, 2, and 4 hrs. The migrated
samples were analyzed under the chemiluminescence detector ChemiDoc XRS+
(Biorad, Hercules, CA). Further, we evaluated the stability of IL-22 mRNA and IL22/nLNPs in both simulated intestinal fluids (SIF) and simulated gastric fluids (SGF).
The IL-22/nLNPs were incubated in SGF or SIF for 4 hrs, respectively. Then the
samples were collected, and electrophoresis was used to determine whether IL-22
mRNA is protected against the gastric condition. For in vivo biodistribution study, the IL22/nLNPs were labeled with lipophilic fluorescent cyanine dye, 1,1'-Dioctadecyl3,3,3',3'-Tetramethylindotricarbocyanine Iodide (DiR’, 10 µM), and administered orally to
mice for 7 consecutive days. On day 8, we euthanized the mice to measure the
biodistribution of DiR’-labeled IL-22/nLNPs in different organs, including the stomach,
small intestine, colon, heart, liver, spleen, lung, kidney, and brain. We also collected
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blood samples to measure the IL-22 protein concentrations in the serum (by ELISA
method) after a 7-day treatment.
3.3.6 In Vitro Transfection of IL-22 Plasmid DNA (pDNA) and mRNA
Colonic epithelial cells (Caco2-BBE, ATCC, Manassas, VA) were used to
transfect IL-22 pDNA or mRNA. Approximately 5x104 cells were seeded on a 24-well
plate prefilled with 0.9 mL Dulbecco’s modified eagle medium (DMEM) per well. When
the cells reached 80% confluency, 2.0 µg of pDNA/nLNPs or 1.0 µg of mRNA/nLNPs
were diluted in 100 µL serum-free media and incubated for 15 min at room temperature,
then the diluted mixtures were added to the 0.9 mL of DMEM media. Samples were
pipetted dropwise to each well and the plates were gently rocked. Supernatants were
collected after 48, 72, and 96 hrs post-transfection, and the expression levels of IL-22
were measured using the ELISA method. In addition, GDNPs- and nLNPs-encapsulated
mRNA were used to compare their IL-22 mRNA delivery efficiency. Caco2-BBE cells
were incubated with GDNPs- or nLNPs-encapsulated IL-22 mRNA and the expression
levels of IL-22 were measured by ELISA after 72 hrs.
3.3.7 In Vivo Expression of IL-22 pDNA in Healthy Mice
C57BL/6 mice (female, 6 to 8-week-old) were purchased from Jackson
Laboratory (Bar Harbor, ME) and acclimatized for a week in the animal facility, with 12 h
light and dark cycles. Mice were divided into two groups (3 mice in each group; Group
1: pDNA/nLNPs, Group 2: mRNA/nLNPs). We fasted all mice for 4 h before gavage and
for 1 h after gavage. Group 1 mice were orally delivered with IL-22 pDNA-loaded nLNPs
and group 2 mice were orally delivered with IL-22 mRNA-loaded nLNPs daily for 3 days.
Dosed volume for each mouse was 200 µL, and the dosage was 200 µg/kg for mRNA
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(4 µg mRNA/mouse) and 400 µg/kg for pDNA (8 µg pDNA/mouse). Mice were
euthanized 4 days after being gavaged with pDNA-loaded nLNP and 1 day after being
gavaged with mRNA-loaded nLNP treatment, respectively. Parts of colon tissues were
collected and homogenized (a detailed method can be found in section 2.9). Tissue
extracts were acquired by centrifugation, and we measured IL-22 protein expression
levels in three parts of the colon (proximal, middle, and distal) following a protocol for
the quantitative mouse ELISA kit (Abcam, Cambridge, UK).
3.3.8 In Vivo Delivery of IL-22 mRNA in Acute Colitis Mice
A total of 20 C57BL/6 mice (female, 6 to 8-week-old, Jackson Laboratory) were
acclimatized for a week in the animal facility, with 12 h light and dark cycles. Mice were
evenly divided into 4 groups (5 mice in each group; Group 1: Healthy control, Group 2:
DSS+PBS, Group 3: DSS+blank nLNPs, and Group 4: DSS+IL-22/nLNPs). Groups 2-4
were treated with 2% DSS (MP Biomedicals, Santa Ana, CA) for 7 days in a row to
induce mild colitis. Before treatment, mice were rested for a day with normal water. All
mice have fasted 4 h before gavage and 1 h after gavage. Then, water, PBS, nLNPs,
and IL-22/nLNPs were gavaged daily for another 7 days to observe the recovery status
of each group. The dosage of IL-22/nLNPs was 200 µg/kg and dosed volume was 200
µL for each mouse. Body weights were measured every day, and fecal samples were
collected every 2 days and stored at 80°C for further inflammatory parameter analysis.
All the mice were euthanized 24 h after the last treatment. Organs (colon and spleen)
were collected, and colon length and spleen weight were measured prior to storage (at 80°C). Colon tissues were cut into three parts: proximal, transverse, and distal. All
experimental procedures involving animals were approved by the Institutional Animal
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Care and Use Committee (IACUC, Georgia State University, Atlanta, GA, No. A20039)
and complied with ethical regulations for animal testing and research.
3.3.9 Measurement of IL-22 Expression in Mouse Colon
Colon tissues were placed in 2 mL Beadbug prefilled microtubes with 2 mm
triple-pure high-impact Zirconium beads (Millipore Sigma, Burlington, MA) and
homogenized in 1x RIPA lysis and extraction buffer (Thermo Fisher Scientific, Waltham,
MA) including protease inhibitor (Roche, Basel, Switzerland) with Beadblaster 24
(Benchmark Scientific, Sayreville, NJ). The homogenizing program was set as 6.0speed m/s, 45-sec shaking, and 15-sec intermissions for 4 cycles at 4°C. Microtubes
containing homogenized colon tissues were centrifuged at 10,000 x g for 20 min at 4°C
to pellet the debris and then carefully transferred the clear supernatants to new 1.5 mL
tubes without any disturbance of pellets. Collected supernatants were used to measure
the quantitative level of IL-22 protein expression in the colon. Prepared 96 well ELISA
plates loaded with samples and capture antibody/detector antibody mixture was
incubated on a tabletop shaker (Thermo Fisher Scientific, Waltham, MA) for 1 hr at
room temperature. Plates were washed well 3 times with wash buffer, and 3,3’,5,5'tetramethylbenzidine (TMB) development solution was added and then incubated in the
dark for 10 min on the shaker again. After the blue color developed, a stop solution was
added to measure OD at 450 nm with a multi-detection microplate reader Synergy 2
(BioTek, Winooski, VT).
3.3.10 Colonic Myeloperoxidase (MPO) Assay
Pre-weighed colon tissues (50 mg/mL) were washed with PBS and homogenized
in 0.5% hexadecyltrimethylammonium bromide (HTAB). Sonication was followed up at
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40% amplitude, 5 sec on/off. Three cycles of freezing and thawing were done at -80°C
and 37°C conditions. Then, the samples were centrifuged at 14,000 rpm for 15 min at
4°C. Clear supernatants and MPO standards were loaded on 96 well plates, and
reactive buffers were added to each well immediately after preparing the solutions. After
colors developed, optical density was read at 450 nm.
3.3.11 Measurement of Fecal Lipocalin-2 (Lcn-2)
Pre-weighed fecal samples were homogenized by vortex for 15 min, and
supernatants were collected after centrifugation at 14,000 x g, 4°C for 15 min. Samples
and standards were loaded on capture antibody pre-coated 96-well plates and
incubated for 2 h at room temperature. After 3 washing steps, detection antibody,
streptavidin-HRP, and substrate solution were added, respectively. Complete aspiration
of each solution was done between the procedures. Optical density was read at 450 nm
and 540 nm immediately after adding the stop solution. Readings were subtracted from
450 nm to 540 nm to correct imperfect data recording.
3.3.12 Quantification of Colonic Cytokine mRNA Expression
Colon extracted and purified total RNA by RNeasy Mini Kit (Qiagen, Hilden, DE)
was used to generate complementary DNA (cDNA) with Maxima cDNA Synthesis Kit
(Thermo Scientific, Waltham, MA). Maxima SYBR Green/ROX qPCR Master Mix
(Thermo Scientific, Waltham, MA) was used to analyze the RNA expression level of proinflammatory cytokines (TNF-a, IL-6, and IL-1b) and anti-inflammatory cytokines (IL-10
and IL-22) with 96-well format thermal cycler (Eppendorf, Hamburg, Germany). The
housekeeping gene, 36B4, was used as a normalization cytokine. Following sense and
anti-sense primers were used: TNF-a: 5’-AGG CTG CCC CGA CTA CGT-3’ and 5’-GAC
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TTT CTC CTG GTA TGA GAT AGC AAA-3’; IL-1b: 5’-TTG ACG GAC CCC AAA AGA
TG-3’ and 5’-AGA AGG TGC TCA TGT CCT CAT-3’; IL-6: 5’-ACA AGT CGG AGG CTT
AAT TAC ACA T-3’ and 5’-TTG CCA TTG CAC AAC TCT TTT C-3’; IL-10: 5’-GGT TGC
CAA GCC TTA TCG GA-3’ and 5’-CTT CTC ACC CAG GGA ATT CA-3’; IL-22: 5’-GTC
AAC CGC ACC TTT ATG CT-3’ and 5’-GTT GAG CAC CTG CTT CAT CA-3’; and
36B4: 5’-TCC AGG CTT TGG GCA TCA-3’ and 5’-CTT TAT CAG CTG CAC ATC ACT
CAG A-3’. Data were recorded and analyzed by Mastercycler ep Realplex version 2.2
(Eppendorf, Hamburg, Germany).
3.3.13 Immunohistochemical Analysis After IL-22 mRNA Treatment
Colonic tissue samples were fixed in 10% buffered formaldehyde overnight at
4°C and stored in 70% EtOH. Samples were embedded in paraffin block to be sectioned
and mounted on glass slides for staining. A standard H&E staining method was used.
Apoptosis and proliferation were examined by immunohistochemical analysis using
TUNEL and Ki-67, respectively. Primary antibodies were incubated with deparaffinized
sectioned samples for 1 hr at room temperature. Sections were then incubated with
secondary antibodies for 30 min.
3.3.14 Fecal Microbiome Analysis by Whole-Genome Sequencing (WGS)
Fresh mouse fecal samples (two pieces for each mouse) were collected and
immediately immersed in the Transnetyx microbiome sample collection tubes (2 mL,
prefilled with 1.5 mL RNA stabilization liquid and glass beads). Then, all the samples
were submitted to the Transnetyx sequencing platform, which leverages shallow
shotgun WGS with a minimum read depth of 2 million paired end reads for the
methodology and provides species/sub-strain level taxonomic resolution on each

NEW THERAPEUTIC TO TREAT COLITIS

40

sample. The analysis includes all microbe types, such as bacteria, viruses, fungi,
protists, and archaea. Data visualization of taxonomy, alpha-, beta- diversity, clustering,
and PCoA were performed at the Onecodex (https://www.onecodex.com) cloud
computing website.
3.3.15 Blood Counting and Blood Chemistry Assay
Blood was collected from the retro-orbital sinus of the mice and all mice were
euthanized after the blood collection, according to the animal protocol (No. A20039,
IACUC, Georgia State University, Atlanta, GA). EDTA-K3 coated tubes (1.3 mL, K3E,
Sarstedt AG & Co. Germany) were used to store blood for further hematological
analyses and Li/Heparin coated tubes (1.3 mL, LH, Sarstedt AG & Co. Germany) were
used to store blood for further blood chemistry test. Blood counting was performed
using an automatic hematology analyzer (VetScan HM5; Abaxis, CA, USA). 50-100 μL
of fresh blood was used for each test and the following hematologic parameters were
tested: WBC, total white blood cells; LYM, lymphocytes; MON, monocytes; NEU,
neutrophils; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit; MCV, mean
corpuscular volume; MCH, hemoglobin amount per red blood cell;

MCHC, mean

corpuscular hemoglobin concentration; RDWc, red cell distribution width cv; RDWs, red
cell distribution width; PLT, platelets; MPV, mean platelet volume; PCT, procalcitonin;
PDWc, Platelet distribution width cv; PDWs, Platelet distribution width. Blood
biochemistry analysis was performed using 100 µL of fresh blood from each mouse. An
automatic hematology analyzer (VetScan VS2; Abaxis, CA, USA) with ABAXIS
comprehensive diagnostic rotor (ABAXIS Europe GmbH, Germany) was employed,
which can quantitate ALT, alanine aminotransferase; ALB, albumin; ALP, alkaline
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phosphatase; AMY, amylase; TBIL, total bilirubin; BUN, urea nitrogen; CA, calcium;
PHOS, phosphorus; CRE, creatinine; GLU, glucose; NA+, sodium; K+, potassium, TP,
total protein; and GLOB, globulin.
3.3.16 Data and Graphic Analysis
Microsoft excel 2013 was used for data recording and processing. GraphPad
Prism 9.01 was utilized for data analysis and visualization. All the data presented are
biological replicates, and the outliers were calculated and removed by the outlier
calculator in GraphPad with an alpha value of 0.05. Significance was determined using
unpaired two-tailed Student’s t-test and differences were noted as significant (*p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001).
3.4 Results
3.4.1 Synthesis of In Vitro Transcribed IL-22 mRNA
In vitro transcription (IVT), which is a simple method for cDNA template-directed
mRNA synthesis, was introduced by Gelder et al. in 1990 (Gelder et al., 1990). Figure 5
demonstrates the simplified steps used to generate the synthetic IL-22 mRNA via IVT.
First, we designed a plasmid DNA (pDNA) containing the targeted IL-22 gene. The
constructed pDNA was affixed with a 3’ poly-A tail to increase the stability and regulate
the translational activity of mRNA. The attached poly-A tail is critical for the ability of the
sequence to interact with poly-A binding protein (PABP) and also protects the mRNA
from 3’ to 5’ nuclease degradation (R., 1991). We then used the purified template DNA
to perform IVT with bacteriophage T7 RNA polymerase and Cap analogs. The original
DNA template was digested by DNase, and the 5’ triphosphate group was removed by
phosphatase to help prevent possible immune responses. We used filtered
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centrifugation to remove unreacted nucleotides, remaining enzymes, and residual salts
to obtain high-quality synthetic IL-22 mRNA. The final concentration of the purified
synthetic IL-22 mRNA was approximately 0.5~1 mg/mL.

Figure 5. Simplified schematic of synthetic IL-22 mRNA generation via in vitro
transcription (IVT). Plasmid DNA was designed to contain the IL-22 gene. IVT,
5’ capping, and polyA tail attachment are steps for improving mRNA stability.
Multiple centrifugations generate purified synthetic IL-22 mRNA.
3.4.2 IL-22 mRNA-Loaded nLNPs (IL-22/nLNPs) Prevent Degradation of IL-22
mRNA
Lipid nanoparticles have shown a robust capability to encapsulate and deliver
variously sized molecules to desired regions in animal models (Puri et al., 2009; Zhao &
Huang, 2014). Having previously identified the lipid compositions of ginger-derived
nanoparticles (GDNPs) (Sung et al., 2020; M. Zhang et al., 2017), we herein used a
simplified

lipid

nano

formulation

containing

digalactosyldiacylglycerol

(DGDG),

monogalactosyldiacylglycerol (MGDG), and phosphatidic acid (PA) to generate nLNPs,
loaded them with the desired mRNA (that encoding IL-22) with the help of a cationic
polymer (turbofectamine, to stabilize and condense the mRNA within the nanoparticles),
and assessed the ability of the generated particles to protect the desired mRNA.
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We checked the particle size and surface zeta potential of the generated mRNAloaded nLNPs using a dynamic light scattering device. The average diameter of the
nLNPs was ~200 nm, and the zeta potential was -29±0.5 mV (Figure 8A-B). Also, the
size and zeta potential of both nLNPs and IL-22/nLNPs were maintained in the PBS
solution for more than 5 hrs (Figure 8F). Thin-layer chromatography (TLC) showed clear
separation of nLNPs components, including DGDG, MGDG, and PA. Also, the TLC lipid
profile of nLNPs is similar to the profile of GDNPs (Figure 8C, right two columns).
Scanning electron microscopy (SEM) was used to examine the morphology of nLNPs.
They appeared to have a generally spherical shape with a particle size of 200 nm
(Figure 8D). Atomic force microscopy (AFM) also visualized the spherical morphology of
nLNPs (Figure 6A). These parameters are similar to those of the original GDNPs (M.
Zhang et al., 2016).
To determine the load efficiency (LE) of mRNA to nLNPs, we quantitated the IL22 mRNA concentrations before and after loading it to nLNPs. The result shows that
nLNPs could yield 67-74% of mRNA loading (Figure 6B), which is excellent for the
encapsulation of a hydrophilic biomolecule such as mRNA. Next, we tested whether
nLNPs could effectively protect the encapsulated mRNA, we performed agarose gel
electrophoresis using free IL-22 mRNA, RNase-treated IL-22 mRNA, and RNasetreated nLNP-encapsulated IL-22 mRNA. Gel imaging showed that free IL-22 mRNA
was degraded by RNase, whereas nLNP-encapsulated IL-22 mRNA was not (Figure
8E). In addition, free IL-22 mRNA, and IL-22/nLNPs were incubated in simulated gastric
fluid (SGF) or simulated intestinal fluid (SIF) for 4 hrs to test whether encapsulated IL-22
mRNA could survive in the GI tract during transportation. As shown in Figure 7, while
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free IL-22 mRNA is unstable in SGF and SIF, nLNPs were able to prevent most of the
encapsulated mRNA from degrading in SGF and SIF. These findings suggest that
nLNPs may protect encapsulated IL-22 mRNAs and thus might be able to deliver this
mRNA to the target region.

Figure 6. A) AFM images of empty nLNPs and IL-22-loaded nLNPs, B) loading
efficiency of IL-22 mRNA to nLNPs (67-74%).

Figure 7. Stability test of IL-22/nLNPs and free IL-22 mRNA in simulated gastric
fluid (SGF) and simulated intestinal fluid (SIF). Free IL-22 mRNA or IL22/nLNPs were incubated in SGF (pH 3.0) or SIF (pH 6.5) for 4 hrs to test the
stability of mRNA with or without nLNPs encapsulation. Samples were then
loaded in 2% agarose gel for 40 min at 100V. The image was taken by
Chemidoc XRS (Biorad, Hercules, CA)
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Figure 8. Characterization of nLNPs and stability test of IL-22/nLNPs. (A-B)
Size and zeta potential of blank nLNPs and IL-22/nLNPs (n=3), (C)
Representative thin layer chromatography (TLC) for nLNP compounds
separation (from left to right D: DGDG, M: MGDG, P: PA, N: nLNPs, G: GDNPs),
(D) Representative SEM images of blank nLNPs and IL-22 loaded nLNPs, the
yellow color was added by Adobe Photoshop (version CS6) allows for easier
lipid nanoparticles identification and differentiation, (E) Stability test of IL-22
mRNA exposed to RNase (with or without nLNPs protection) by 2% agarose
gel electrophoresis, and (F) Size and zeta potential stability test of blank nLNP
and IL-22/nLNP in PBS solution at room temperature.

IL-22 concentration (pg/mL)
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Figure 9. In vitro transfection efficiency comparison between IL-22/nLNPs and
IL-22/GDNPs (****P<0.0001, ns: nonsignificant, n=12).
3.4.3 IL-22 mRNA is More Efficient Than IL-22 pDNA for Expressing IL-22 Protein
in Intestinal Epithelial Cells In Vitro
The major expected advantage of mRNA over DNA for gene delivery is that
mRNA has a higher transfection efficiency: mRNA can directly enter the cytoplasm to
undergo immediate translation, whereas pDNA must first cross the nuclear membrane
to undergo transcription. To compare the transfection efficiency of pMRNAxp-IL-22
mRNA and CD813-IL-22 pDNA, we transfected nLNPs loaded with each formulation to
Caco-2 BBE cells under identical culture and treatment conditions, collected the cell
culture medium after 72 h of incubation, and measured the level of IL-22 by ELISA. As
shown in Figure 10, cells transfected with IL-22 mRNA-loaded nLNPs generated over 3
pg/mL of IL-22 protein, whereas those transfected with pDNA-loaded nLNPs showed
only a slight increase to 1.8 pg/mL. This demonstrates that the nLNP-mediated delivery
of IL-22 mRNA is far more efficient than that of IL-22 pDNA in increasing the protein
expression of IL-22 in vitro. We also compared the transfection efficiency between
GDNPs and nLNPs encapsulated mRNA formulations, data shows that reversely
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engineered nLNPs yield the same degree of transfection efficiency as the GDNPs

IL-22 concentration (pg/mL)

(Figure 9).
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Figure 10. IL-22 mRNA is more efficient than IL-22 pDNA for expressing IL-22
protein in intestinal epithelial cells (Caco2-BBE). Significant increase of IL-22
by transfection of nLNPs encapsulated IL-22 mRNA compared to encapsulated
pDNA or controls (*P<0.05, ****P<0.0001, n=6).
3.4.4 Oral delivery of IL-22/nLNPs to the colon induces colonic IL-22 protein
expression
As mRNA is easily degraded in the GI tract, the main function of a colon-targeting
delivery system must be to maintain the stability of mRNA when passing through the GI
tract. Previous studies demonstrated that an orally delivered subgroup of GDNPs could
effectively escort encapsulated drugs and siRNAs to the colon (M. Zhang et al., 2017),
indicating that GDNPs maintain their nanostructure while transiting the GI tract. LCMS/MS-based lipid analysis showed that the lipid composition of the GDNPs
nanostructure is DGDG, MGDG, and PA, and that they occur in a respective ratio of
3:2:5 (M. Zhang et al., 2016). The three lipids together were found to comprise more
than 90% of the lipids in the subgroup of colon targeting GDNPs. Here, we used the
same ratio to construct well-defined nLNPs that contained only these three major lipids.
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After thin-film hydration, the constructed nLNPs were found to have characteristics
(such as morphology, size, and zeta potential) nearly identical to those of the original
colon-targeting GDNPs.
Given that a quick increase of IL-22 in the intestinal mucosa can accelerate the
resolution of inflammation (Xiao et al., 2018) whereas prolonged IL-22 upregulation may
link to colitis-associated colon cancer (Mizoguchi et al., 2018), we investigated whether
oral delivery of nLNP-encapsulated IL-22 mRNA to healthy mice could boost their
intestinal protein expression of IL-22 much quicker compared to oral delivery of nLNPloaded IL-22 pDNA. In this context, both IL-22 mRNA and pDNA were administered 3
days in a row, mRNA-treated mice were euthanized 1-day post-treatment whereas the
pDNA group was euthanized 4 days after the treatment. As seen in Figure 11, both IL22 mRNA and pDNA altered the colonic IL-22 expression but in a different pattern.
Importantly, IL-22 mRNA was able to achieve the same degree of effect in just one day
after treatment. The different efficacy patterns yielded from IL22 mRNA and pDNA is a
phenomenon that requires more investigation. These findings suggest that oral delivery
of IL-22/nLNPs could be a promising approach for instantly inducing colonic IL-22
protein expression.
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Figure 11. In vivo treatment of IL-22 pDNA and mRNA and protein expression
level in three parts of the colon, including proximal, middle, and distal. (A-C) 3day-treatment of IL-22 pDNA and euthanized 4 days later, (D-F) 3-daytreatment of IL-22 mRNA and euthanized 1 day later (*P<0.05, ns:
nonsignificant, n=3).
3.4.5 Oral Administration of IL-22/nLNPs Accelerates Healing in a Mouse Model of
Intestinal Wound Healing
After confirming that IL-22/nLNPs could instantly increase colonic IL-22
expression in healthy mice, we next tested whether this enhancement could expedite
the healing of acute colitis. We employed the DSS-induced mouse model of acute
colitis, wherein DSS causes epithelial lining loss and mucosal barrier damage to model
human IBD. DSS was administered for the first 7 days to induce mild colitis, and regular
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water was administered for 1 day to allow the mice to rest (Figure 13A) and reduce the
risk that the nLNPs would be disturbed by any DSS remaining in the GI tract (Laroui et
al., 2012), and then IL-22/nLNPs, blank nLNPs, or PBS were orally administered for
another 7 days. Fecal samples and body weight data were also collected every 2 days
throughout the experiment. At the end of this treatment (day 15), we found that IL22/nLNP-treated mice had recovered their body weight to near that of the healthy
mouse group (which received only water and showed a natural increase in body weight
over time), whereas the PBS and blank nLNP groups showed significantly lesser
recovery of body weight than IL-22/nLNP-treated group. (Figure 13B).
We also investigated colon length and spleen weight as additional inflammatory
parameters. The average colon length of the IL-22/nLNP-treated group was greater
than those of the PBS- and blank nLNP-treated groups (Figure 13C), whereas the
spleen weight did not differ significantly between treated groups (Figure 13). We
collected stool samples during the treatment and measured the fecal lipocalin-2 (Lcn-2)
level, which is a sensitive and non-invasive biomarker for intestinal inflammation in
murine models. As shown in Figure 13D, 7-day 2% DSS treatment was associated with
a significant increase of fecal Lcn-2 in all groups, compared to the healthy control group.
On day 16, the Lcn-2 level was dramatically decreased (>50%) in the IL-22/nLNP group,
but not significantly altered in the PBS and blank nLNP groups. These findings
suggested that oral administration of IL-22 mRNA-loaded nLNPs significantly speeds up
the healing phase in a mouse model of intestinal wound-healing.
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Figure 12. Spleen weight and spleen to body weight ratio comparing DSS
wounded and IL-22/nLNPs treated mice to other groups (healthy, PBS-treated,
and blank nLNPs-treated). (*P<0.05, ns: nonsignificant, n=3).
After the 7-day IL-22/nLNP treatment, we expected that IL-22 expression would
be upregulated in the colon of DSS-induced colitis mice. We thus measured IL-22 in the
proximal, middle, and distal colon. Our results revealed that the concentrations of IL-22
protein in all sections were significantly increased after IL-22/nLNP treatment (Figure
13F). Neutrophil accumulation in the inflamed intestinal mucosal layer is a prominent
feature in UC. Inflammatory severity is often correlated with colonic myeloperoxidase
(MPO) activity, representing neutrophil accumulation into the mucosa during intestinal
inflammation can be measured. We found that the MPO activity of the IL-22/nLNPtreated group was significantly lower than those of the PBS or blank nLNP groups
(Figure 13E), indicating that the nLNP-delivered IL-22 also reduced the inflammation
associated with neutrophil accumulation.
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Figure 13. Oral administration of IL-22/nLNPs accelerates healing in a mouse
model of intestinal wound healing (A) Timeline of IL-22-mRNA treatment (7
days) on DSS-wounded mice (7 days), (B) Body weight change, (C) Colon
length, (D) Fecal lipocalin-2 level, and (E) Colonic myeloperoxidase (MPO)
level after 7 day-treatment (*P<0.05, ***P<0.001, ns: nonsignificant, n=5).
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3.4.6 Oral Delivery of IL-22/nLNPs Suppresses ColonicEexpression of ProInflammatory Cytokines
Several cytokines are known to orchestrate the initiation, evolution, and
resolution of pathophysiological progress in UC, and their concentrations are taken as
crucial indicators of disease severity. Therefore, we examined the expression levels of
the critical pro-inflammatory cytokines, TNF-α, IL-1β, and IL-6. Studies have shown that
TNF-α exerts its pro-inflammatory effects by amplifying the downstream cytokines, IL-1β
and IL-6, which subsequently modulate adhesion molecule expression, fibroblast
proliferation, procoagulant factors, acute-phase cytotoxic/apoptotic responses, and
general apoptosis. We found that oral administration of IL-22 mRNA-loaded nLNPs
downregulated IL-1β, IL-6, and TNF-α (Figure 14), which have been implicated in the
inflammatory responses responsible for intestinal mucosal damage (Nikolaus et al.,
1998; Williams, 2001).

Figure 14. Oral delivery of IL-22/nLNPs suppresses colonic expression of proinflammatory cytokines. Quantitative measurement of pro-inflammatory
cytokines alteration (TNF-α, IL-6, and IL-1b) (*P<0.05, **P<0.01, ns:
nonsignificant, n=5).
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3.4.7 Histological Analysis Shows that Oral Administration of IL-22/nLNPs
Accelerates the Healing of Injured Intestinal Mucosa
Histological analysis is a powerful tool for evaluating the level of inflammation in
damaged colonic tissues. Three main histological parameters can be taken as reflecting
the severity of inflammation: morphological changes of crypts, inflammatory cell
infiltration, and overall mucosal structure. We examined whether orally administered IL22/nLNPs could have therapeutic impacts on these histological scores. As shown in
Figure 15A, healthy control and IL-22/nLNP-treated colon tissues displayed well-defined
epithelial and no leukocyte infiltration in the mucosa, whereas the PBS group showed
evidence of severe colonic damage, such as inflammatory cell infiltration, crypt
distortion, and epithelial thickening. As a result, the histology score of the IL-22/nLNPtreated group was significantly lower than that of the PBS group (Figure 15C).
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Figure 15. H&E-stained and Ki-67 (proliferation)-stained colon tissues after
treatment of IL-22/nLNPs on DSS-wounded mice. (A) Top images (5x) and
bottom images (20x) show magnification of stained colon tissues for each
group (healthy, DSS+PBS, and DSS+IL-22/nLNPs), (B) Ki-67 staining image of
colon tissues, (C) histology score of H&E staining, and (D) proliferation cell
percentage of Ki-67-stained colon tissues (*P<0.05).
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Oral Administration of IL-22/nLNPs does not Affect the Gut Microbial
Composition
The gut microbiota supports the physiological and immunological functions of the
GI tract by interacting with the intestinal mucosal barrier and modulating host
metabolism and immunity. To study the impact of orally delivered IL-22 mRNA-loaded
nLNPs on the gut microbiota, we collected fecal samples from control and treatment
groups and used whole-genome sequencing (WGS) to investigate their gut microbiota
composition. We then compared the taxonomic profile and microbial composition of
each group at the phylum level. Our results indicated that oral administration of IL22/nLNPs did not noticeably impact the intestinal microbiota composition. The observed
taxonomy and species diversity (Shannon index, Simpson index) showed no significant
difference between the groups with or without IL-22/nLNP treatment (Figure 17A). The
similarities and differences of the groups were visualized and compared by conducting a
principal coordinate analysis (PCoA) (Figure 17B). Each colored dot represents an
individual mouse (green, untreated; purple, PBS; navy, blank nLNPs; and orange, IL22/nLNPs), and the distance between each group represents the degree of difference.
While the gut microbiota of DSS-treated mice was distinct from those of healthy mice
even after the 7-day recovery phase, those of the nLNP or IL-22/nLNP groups did not
exhibit any between-group compositional difference.
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Figure 16. Measurement of alpha diversity through Shannon index and
Simpson index analysis. (ns: nonsignificant, n=5).
We generated a donut graph to visualize the microbial distribution within each
group and identify the top seven most abundant phyla (Figure 17C). Firmicutes and
Bacteroidetes were dominant in the healthy mouse group, but Verrucomicrobia
represented a large portion of the populations in all 2% DSS-treated groups. A Venn
diagram was used to display the sharing of bacterial phyla between and across the
groups. The total numbers of bacterial phyla in each group were as follows: healthy,
125; PBS, 110; blank nLNPs, 122; and IL-22/nLNPs, 129. Ninety-six phyla overlapped
across all four groups (Figure 17D). We also generated a heatmap and bar graph
showing the relative microbial abundances and found that Bacteroidetes was the most
abundant phylum in all groups, and there were more Firmicutes in the healthy group
(Figures 17E). To further investigate the top two most abundant phyla, Bacteroidetes
(B) and Firmicutes (F), we performed a side-by-side comparison and measured the F to
B ratio (F/B). The F/B was highest in the healthy group compared to the other groups
(Figure 17G-H). Distance matrix measurements between the groups were assessed
using hierarchical clustering analysis, which revealed that Bacteroidetes and Firmicutes
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are relatively more abundant in all groups compared to other species (Figure 17F).
Collectively, our data demonstrate that oral administration of IL-22 mRNA-loaded
nLNPs had no noticeable impact or apparent direct action on the gut microbiota
composition.
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Figure 17. Oral administration of IL-22/nLNPs had no noticeable impact on the
gut microbiota composition. (A) Observed taxa showing diversity calculated
based on the operational taxonomic unit (OTU), (B) Principal coordinate
analysis (PCoA) of the weighted UniFrac distance matrix of fecal microbiota
from untreated, PBS, blank nLNPs, and IL-22/nLNPs group, (C) Donut graph of
microbial composition at the phylum level, (D) Venn diagram analysis of
common bacterial phylum of each group, (E) heatmap of relative abundance of
microbial distinguishment at the phylum level, (F) relative abundance of the
microbiome at the phylum level, (G) relative abundance in percentages of
Bacteroidetes and firmicutes, and (H) Firmicute to Bacteroidetes ratio
(*P<0.05, ns: nonsignificant, n=5).
3.5 Discussion and Future Direction
IL-22

primarily

contributes

to

intestinal

health

by

regulating

epithelial

homeostasis, which is established by building a tight epithelial barrier, regulating cell
growth and permeability, and secreting mucus and antimicrobial proteins (Keir, Yi, Lu, &
Ghilardi, 2020). The IL-22-mediated production of mucin in mucosal tissues is the first
line of defense against commensal bacteria and pathogens (Johansson & Hansson,
2016). Specialized goblet cells generate the inner mucus layer in the colon to protect
the host under normal conditions (Ermund, Schutte, Johansson, Gustafsson, &
Hansson, 2013). Disease-induced IL-22 deficiency can lead to inhibition of the goblet
cell hyperplasia normally seen in response to an infection (Turner, Stockinger, &
Helmby, 2013). The presence of IL-22 and the production of membrane-bound mucins,
such as Muc-1, Muc-3, and Muc-10, contribute to protecting the mucus layer from
colitis-associated destruction and restoring goblet cells (Corfield, Carroll, Myerscough, &
Probert, 2001; Ho et al., 2006; Shirazi, Longman, Corfield, & Probert, 2000). Recent
investigations indicate that IL-22-mediated Muc-2 and Muc-3 expression helps alleviate
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DSS-induced colitis (Van der Sluis et al., 2006). These studies suggest that lack of IL22 may cause goblet cell deficiency and prevent healthy mucus layer development.
Thus, we speculated that targeted delivery of IL-22 to the colon might effectively
improve mucosal wound healing following colitis. Sugimoto et al.

(Sugimoto et al.,

2008) confirmed that local microinjection of IL-22 DNA to the mouse colon enhanced
STAT3 activation within colonic epithelial cells and induced STAT3-dependent
expression of mucus-associated molecules and reinstitution of mucus-producing goblet
cells. However, it has been reported that long-term treatment with IL-22 or continuous
activation of the IL-22 pathway may increase the risk of colitis-associated cancer
(Arshad, Mansur, Palek, Manzoor, & Liska, 2020; Mizoguchi et al., 2018).
Recent decades have seen tremendous progress in the development of gene
delivery techniques and their use in regulating disease-related proteins (Goverdhana et
al., 2005; Nimesh, Halappanavar, Kaushik, & Kumar, 2015). Both mRNA and DNA have
been widely studied for their ability to upregulate a target protein in vitro (Buck,
Grossen, Cullis, Huwyler, & Witzigmann, 2019; Veiga et al., 2018). Generally, DNA
delivery is associated with delayed efficacy because the DNA must reach the nucleus to
regulate protein expression. This nature of DNA is seen as a barrier to developing DNAbased therapeutics (Phillips, 2001). In contrast, an mRNA needs only to reach the
cytoplasm, and thus its delivery can yield a more rapid increase in the target protein
level (Wadhwa, Aljabbari, Lokras, Foged, & Thakur, 2020). Here, we examined both
mRNA and pDNA for their ability to enhance the IL-22 protein level of cultured colonic
epithelial cells. Consistent with the general thinking described above, we found that
mRNA delivery yielded more efficient IL-22 protein production compared to pDNA
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delivery. However, mRNAs are inherently unstable and vulnerable to degradation by
ribonucleases. Thus, it is important to stabilize mRNAs for their in vivo delivery (Guan &
Rosenecker, 2017). It is well known that modifying mRNA structural elements,
particularly the 5’ cap, 5’ and 3’ untranslated regions (UTRs), coding region, and poly-A
tail (which interacts with PBAPs to prevent mRNA degradation), can help reduce the
excessive immunogenicity of an mRNA and improve its intracellular stability and
translation efficiency (M. Z. Wu, Asahara, Tzertzinis, & Roy, 2020). We thus added a
poly-A tail to our construct to improve the mRNA’s stability. Purification of the mRNA is
also necessary to ameliorate the instability and immunogenicity of mRNA (Baiersdorfer
et al., 2019). As byproducts remaining in the IVT IL-22 mRNA solution may activate
unexpected immune responses, we carefully purified the mRNA by removing
triphosphate, unreacted nucleotides, remaining enzymes, and residual salts.
Subsequent toxicity results, including histology, spleen index (Figure 12),
complete blood count (Figure 18), blood chemistry (Figure 20), and FACS analysis
(Figure 21) demonstrated that our IL-22 mRNA did not generate any immune response
associated with side effects. The biodistribution study also showed that orally delivered
IL-22/nLNPs were restricted to the colon and stomach (a direct contact), with no
observable distribution in other organs (Figure 19A-B) and IL-22 protein expression was
not increased in the blood (Figure 19C). Such property of nLNP-based oral gene
delivery may largely improve the safety (reduce the systemic toxicity) of the treatment.
However, we noticed that our present work uses a non-modified IL-22 open reading
frame. We could conceivably improve the translation efficiency (and protein expression)
of IL-22 in our system by performing codon optimization of the open reading frame.
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Recently, codon-optimization of mRNAs has been exploited to impact the protein
production rate (Mauro, 2018). For example, N1-methyl-pseudouridine nucleotide
substitution was found to increase base pair stability and thereby improve mRNA
translation (Mauger et al., 2019). We are currently looking to optimize the IL-22 open
reading frame to increase the translation efficiency of the IL-22 mRNA in our system.

Figure 18. Complete blood count. (A) white blood cell, (B) lymphocyte, (C)
neutrophil, (D) mononuclear, (E) red blood cell, and (F) platelet. (ns:
nonsignificant, n=5).
At present, most gene formulations are delivered intravenously to increase their
systemic bioavailability, and the therapeutics reach the target by either active targeting
(e.g., antibody-guided targeting) or passive targeting (following the blood circulation).
These gene delivery paths are indirect, and the therapeutics may cause unexpected
side effects. Oral delivery is considered to be a better option, assuming that the colontargeting formulation is sufficiently stable during GI tract transit. Having established that
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orally delivered GDNPs target the colon (C. Yang et al., 2021; M. Zhang & Merlin,
2018), we analyzed the chemical components of GDNPs and set out to reverse
engineer the nanostructure. LC-MS/MS-based lipid analysis revealed that GDNP lipids
contain high percentages of the galactolipids, DGDG and MGDG, as well as the
phospholipid, PA. The two galactolipids are commonly found in plant leaves, where they
form the stable lipid bilayer structure of the chloroplast. Together, these three
components comprise more than 90% of the lipids isolated from GDNPs (Sung et al.,
2020; M. Zhang et al., 2016; M. Zhang et al., 2017). Interestingly, many plant-derived
nanoparticles (e.g., those from tea leaves, grape leaves, and ginger) lack cholesterol
but are still sufficiently stable to target the lower part of the GI tract. Here, we mixed
DGDG, MGDG, and PA at the ratio found in GDNPs, and found that this mixture
successfully formed nanosized particles in PBS. To encapsulate the IL-22 mRNA, we
used a cationic polymer to stabilize the mRNA and neutralize its native negative charge,
which would block its encapsulation into the negatively charged reversely engineered
nLNPs. The cationic polymer, turbofectamine, has two positively charged head groups
connected by a 5-10 carbon/heteroatom linker and served as an anchor to stabilize the
mRNA within the nLNPs. Nanocarriers such as nLNPs were generally internalized
through endocytosis. Once they reach target cells, nLNPs might be internalized by
multiple mechanisms, including micropinocytosis, and clathrin-mediated and caveolaemediated endocytosis (X. Hou, T. Zaks, R. Langer, & Y. Dong, 2021). The endocytic
pathway depends on the properties of the nanoparticle and the cell type. Endosomal
escape is crucial for effective mRNA delivery. Although the mechanism has not yet
been fully understood, positively charged lipids such as turbofectamine may facilitate
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electrostatic interaction and fusion with negatively charged endosomal membranes,
resulting in the leak of mRNA molecules into the cytoplasm (X. Hou et al., 2021;
Xucheng Hou, Tal Zaks, Robert Langer, & Yizhou Dong, 2021; Z. Wu & Li, 2021).
Synthetic nanoparticles offer a more consistent end product compared to their
naturally derived counterparts and have been applied in clinical studies. For example,
lipid nanoparticles (LNPs) have been used to successfully deliver mRNAs to prevent the
spread of SARS-CoV-2 (X. Hou et al., 2021; Khurana et al., 2021). Due to the rise of
mRNA therapeutics, the pharmaceutical industry has faced a vast paradigm shift in
developing this new class of gene therapeutics and updating drug development plans
from focusing on small molecules to emphasizing gene-based drugs (Foldvari et al.,
2016; Sripriyalakshmi, Jose, Ravindran, & Anjali, 2014; M. Wang, Yu, Liang, Lu, &
Zhang,

2016;

Yin,

Kauffman,

&

Anderson,

2017).

Indeed,

gene-based

biopharmaceuticals have shown remarkable benefits and efficacy over traditional
chemical drugs, with far fewer adverse effects and higher specificity (Sahin, Kariko, &
Tureci, 2014; Zhong et al., 2021). The advantage of using well-defined reverseengineered nLNPs as a gene-drug delivery system, compared to the original plantderived nanoparticles, is that the nLNPs have a consistent chemical composition and
characteristics, with a reduced batch-to-batch variation. In addition, our reverseengineered nLNPs essentially inherit the original galactolipid/phosphoric lipid ratio, lipid
bilayer structure, and colon-targeting of GDNPs. Because DGDG, MGDG, and PA are
abundant in many green leafy plants (Cook, Lupette, & Benning, 2021; Reszczynska &
Hanaka, 2020; Yu, Lin, & Li, 2020), it might be feasible to mass-produce nLNPs from
these three lipids.
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Figure 19. Biodistribution of DiR-tagged IL-22/nLNPs in mouse organs after 7day consecutive oral administration. A) Representative picture shows the
fluorescence detected in different mouse organs (stomach, caecum, lung,
brain, kidney, spleen, heart, liver, colon, and small intestine) B) Quantitative
measurement of fluorescence detected in organs. C) Serum IL-22 quantitation
by ELISA test for samples from each group (healthy, PBS, Blank nLNPs, and
IL-22/LNPs). (****P<0.0001, ns: nonsignificant, n=4 or 5).
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Figure 20. Blood biochemistry analysis. (A) aminotransferase, (B) albumin, (C)
alkaline phosphatase, (D) amylase, (E) bilirubin, (F) nitrogen, (G) calcium, (H)
phosphorus, (I) creatine, (J) glucose, (K) sodium, (L) potassium, (M) total
protein, and (N) globulin.

NEW THERAPEUTIC TO TREAT COLITIS

67

Here, we show that our reversely engineered nLNPs could be embodied as a
robust drug delivery system that targets encapsulated IL-22 mRNAs to the colon tissue
and induces colonic IL-22 protein expression. We believe that the targeted cells are
most likely to be the intestinal epithelial cells. However, further experiments will be
needed to rule out the possibility that other cells, such as macrophages, could take up
the IL-22 mRNA and express the observed colonic IL-22 protein after the oral
administration of IL-22 mRNA-loaded lipid nanoparticles.

Figure 21. Toxicity test of blank nLNPs against CD4+ and CD8+ by
FACS analysis and quantitative fold change over control group
This study demonstrates that oral delivery of IL-22/nLNPs can target the injured
intestinal mucosa and accelerate the healing phase in a mouse model of intestinal
wound healing. Our results demonstrate that orally delivered IL-22/nLNPs induce
colonic IL-22 protein expression and might accelerate the restitution of intestinal barrier
function, as shown by our histological results (Figure 15). These findings agree with
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previous studies showing that IL-22 regulates the homeostasis of the intestinal
epithelium and is critical for the regeneration of the intestine under inflammation (X.
Zhang et al., 2019). We suggest that the IL-22-mediated reduction of pro-inflammatory
cytokines, such as TNF-α, IL-1β, IL-6, and the mucosal infiltration of neutrophils, as
observed in our experiments (Figure 14) may be conducive to the restitution of the
intestinal barrier function. Interestingly, we found that orally administrated IL-22/nLNPs
had no direct action on the gut microbiota composition and that our IL-22 mRNA
treatment appears to target the colonic mucosa.
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4 ISOLATION, PURIFICATION, AND CHARACTERIZATION OF GINGER-DERIVED
NANOPARTICLES (GDNPS) FROM GINGER, RHIZOME OF ZINGER OFFICINALE
Copyright © 2022, Published by the Bio-protocol,
DOI.ORG/10.21769/BioProtoc.3390
4.1 Abstract
Factors implicated in the pathophysiology of intestinal inflammation include
defects in intestinal epithelial barrier function, abnormal immune responses, and
activities of the gut microbiota. Current agents used to treat human Inflammatory
Bowels Disease (IBD), chronic inflammation of digestive tract, have serious side effects.
In addition, most of these treatments target the damaging factors while not providing
pro-healing factors that repair the damaged intestine. Here we provide a method to
isolate, purify and characterize a specific population from ginger (ginger-derived
nanoparticles: GDNPs 2) with anti-inflammatory activities. GDNPs 2 as a drug vehicle
are a novel natural, nontoxic delivery system, which target the inflamed intestinal
mucosa, blocks damaging factors while promoting pro-healing factors and could easily
be developed for large-scale production aimed at the treatment of IBD.
4.2 Introduction
Efforts to develop new drug-based therapeutic approaches against Intestinal
Bowel Disease (IBD) must overcome several challenges, including issues of delivery,
potential off-target effects, safety, toxicity, large-scale production costs, and tissue
specificity (Chen et al., 2017). We and other groups have recently demonstrated that
artificially synthesized nanoparticles may be used to target low doses of drugs (e.g.,
siRNAs, proteins, and peptides) to specific cell types or tissues (Xiao et al., 2017).
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However, the nanoparticles synthesized to date have two major limitations: i) each
constituent of the synthesized nanoparticles must be examined for potential in vivo
toxicity before clinical application; and ii) the production scale is limited. The use of
nanoparticles derived from natural sources may overcome these limitations of synthetic
nanoparticles. Here, we provide a safe and cost-effective sucrose gradient
ultracentrifuge method to isolate, purify and characterize a specific population of
nanoparticles from ginger (ginger-derived nanoparticles: GDNPs 2) with antiinflammatory activities. GDNPs 2 enable encapsulation of various types of therapeutic
agents such as DNA, RNA, and antibodies. Loading therapeutic agents in gingerderived nano lipids can be found in a separate publication (Zhang et al., 2017). GDNPs
2 represents a novel natural, nontoxic delivery system that targets the inflamed
intestinal mucosa, blocks damaging factors while promoting healing factors and may
easily be developed for large-scale production aimed at the treatment of IBD.
4.3 Materials, Reagents, and Equipment
•

Pipette tips 0.1-10 µl, 1-200 µl, 100-1,000 µl (Sorenson Bioscience, catalog
numbers: 70600, 70520, 70540)

•

Pipettes 0.5-10 µl, 10-100 µl and 100-1,000 µl (Eppendorf, catalog number: 13684-251)

•

Thin wall, ultra-clear 13.2 ml, 14 x 89 mm ultracentrifuge tubes (Beckman
Coulter, catalog number: 344059)

•

Thick wall, 38 ml, 25 x 89 mm centrifuge tubes polycarbonate (Beckman Coulter,
catalog number: 355631)
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Thick wall, 70 ml, 38 x 102 mm centrifuge bottles polycarbonate (Beckman
Coulter, catalog number: 355655)

•

Eppendorf Safe-Lock Tubes, 1.5 ml (Eppendorf, catalog number: 022363204)

•

50 ml conical tubes (Denville Scientific, catalog number: C1062-P)

•

Formvar®-coated copper grids (Electron Microscopy Sciences, catalog number:
FCF300-CU-SC)

•

Filter paper (VWR, catalog number: 28313-068)

•

Sterile cell strainer 40 µM (Fisher Scientific, catalog number: 22-363-547)

•

Capillary cell & plastic cap (Malvern, catalog number: DTS 1070)

•

Sucrose (Calbiochem, catalog number: 8510)

•

Protein quantification assay kit (Bio-Rad, catalog number: 5000002)

•

Phosphate-buffered Saline (Corning, catalog number: 21-040-CV)

•

Simulated intestinal fluids (RICCA Chemical, catalog number: 7109-16)

•

Simulated gastric fluids (RICCA Chemical, catalog number: 7108-16)

•

Uranyl acetate (Electron Microscopy Sciences, catalog number: 22400-4)

•

Mica sheet (Electron Microscopy Sciences, catalog number: 71855-15)

•

Sucrose gradient (8, 30, 45, 60%)

•

1% uranyl acetate solution

•

Juicer (Breville, model: BJE200XL)

•

Sorvall ST 16R centrifuge (Thermo Fisher Scientific, catalog number: 75004381)

•

Optima L-90K Ultracentrifuge (Beckman Coulter, catalog number: 969349)
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Rotors: J-Lite Series JLA 16.250 16,000 RPM (Beckman Coulter, Serial number
O8U 3761), Type 45 Ti 45,000 RPM (Beckman Coulter, Serial number
99E.2785), SW 32 Ti 32,000 RPM (Beckman Coulter, Serial number 11U 2963)

•

Zetasizer (Malvern, model: Nano-ZS90)

•

Particle size analyzer (Brookhaven Instrument Corps, model: 90PLUS)

•

Atomic force microscopy instrument (Seiko Instrument Inc., model: SPA400)

•

Transmission electron microscope (Carl Zeiss, model: LEO 906E)

•

Milli-Q advantage A10 water purification system (Millipore-sigma, catalog
number: C10117)

•

Semi-micro cuvettes, clear 1.5 ml (Sigma, catalog number: BR759115)

•

Ultrasonic bath (Branson, catalog number: 3510MTH)

•

Fluorometric microplate reader (Biotek, model: Synergy 2)

•

pH meter (Sper Scientific, catalog number: 860031)

•

-80 °C freezer (So-Low, model: PV85-21)

4.4 Procedure
4.4.1 Isolation
-

Wash 1 kg of roughly peeled ginger thoroughly with tap water.

-

Grind sliced ginger with blender to obtain juice (Figure 22).

-

Centrifuge approximately 550 ml of the ginger juice at 3,000 x g for 20 min at RT.

-

Centrifuge again at 10,000 x g for 2 h at RT to remove large fibers.

-

Collect the supernatant and equally distribute (~45 ml) into twelve 70 ml capacity
tubes.
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Ultracentrifuge the collected supernatant at 4 °C, 150,000 x g for 2 h (Use Type
45 Ti 45,000 RPM). Ultracentrifuge 6 tubes two times.

-

Remove supernatant and suspend the pellet in each tube in 5 ml PBS through
ultrasonic dispersion. After proper pipetting, all the nanoparticle pellets should be
well suspended in PSC solution. If insoluble pellet exists, a cell strainer can be
used to remove the insoluble pellet before loading to the gradient centrifugation.

Figure 22. Ginger juice extraction. Sliced ginger is squeezed in the juicer to
obtain juice for nanoparticle isolation and purification.
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Figure 23. Sucrose gradient ultracentrifugation. GDNPs were added to 8,
30, 45 % of sucrose gradient and ultracentrifuged for purification.
4.4.2 Purification
-

Prepare twelve 38.5 ml capacity tubes filled with 10 ml of each sucrose solution
in the order of 8%, 30% and 45% from top to bottom.

-

Transfer 5 ml of the PBS suspended pellet from each tube to discontinuous
sucrose gradient (8%, 30%, 45% [gram/volume]) in the 12 tubes and
ultracentrifuge with SW 32 Ti rotor at 4 °C, 150,000 x g for 2 h. Ultracentrifuge 6
tubes two times (Figure 23).

-

Collect ~2 ml of band 2 and ~0.6 ml of band 1 respectively from 8/30% and
30/45% interfaces by gently dipping pipette tips into the sucrose gradient solution
(see Data analysis).

-

Ultracentrifuge the collected bands at 4 °C, 100,000 x g for 45 min (use Type 45
Ti 30,000 RPM), remove the supernatant.

-

Wash the pellet with 1 ml PBS to remove the remaining sucrose and then
suspend the pellet in 1 ml PBS through ultrasonic dispersion.
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Measure the concentration of obtained GDNPs (0.25~1.25 mg/ml) using protein
quantification assay kit (follow the manufacturer’s manual) and microplate reader
at absorbance of 750 nm.

-

For short term storage (less than 3 months), GDNPs can be suspended in PBS
and stored at -80°C. Long term stability has not been evaluated (Only Band 2 for
Characterization; Discard Band 1).

4.4.3 Characterization
Evaluate the nanoparticle for its in vitro stability
-

Add 1 ml of nanoparticles (1 mg/ml) to 9 ml of simulated gastric fluid (SGF) and
simulate intestinal fluid (SIF) in a separate tube.

-

Mix thoroughly by inverting tubes.

-

Dilute 0.2 ml of mixture into 1.8 ml PBS.

-

Determine the particle size and zeta potential before incubation (follow Steps C2
and C3 below).

-

Incubate the mixture in 37 °C water bath for 30 min.

-

Determine the particle size and zeta potential after incubation.
Measure particle size (Figure 24)

-

Dilute 0.2 ml of mixture into 1.8 ml PBS.

-

Carefully add all the diluted mixture to a cuvette without bubbles.

-

Insert the cuvette to the particle analyzer chamber.

-

Determine the size of particles.
Measure zeta potential (Figure 25)

-

Carefully add 0.8 ml of mixture to capillary cell.
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Cover the capillary cell with plastic cap.

-

Insert the cell to the chamber of zeta potential analyzer.

-

Determine the numbers for the sample at neutral pH.
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Figure 24. Measurement of band 2 ginger nanoparticle size. Approximate
nanoparticle size was determined to be ~115.8 nm in radius.

Figure 25. Measurement of zeta potential of band 2 ginger nanoparticle.
Approximate zeta potential measured by Malvern zetasizer was ~-12 mV at pH
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6.
Acquire transmission electron microscopy (TEM) image (Figure 26)
-

Deposit a drop of sample onto the surface of a formvar-coated grid.

-

Add 1% uranyl acetate on top of the sample and wait for 15 s.

-

Carefully absorb the sample and uranyl acetate with tissue without touch the
surface.

-

Dry the sample at room temperature for 5 min.

-

Scan the sample image with a transmission electron microscope.

Figure 26. TEM (Transmission electron microscopy) image of GDNPs 2

Acquire atomic force microscopy (AFM) image (Figure 27)
-

Deposit 1 μl of nanoparticle sample to mica sheet.

-

Dry the sample at room temperature.

-

Gently rinse the mica sheet with 2.5 μl of distilled water three times.

-

Dry the sample at room temperature again.

-

Leave it until the sample become flat.
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Scan the sample with area of about 4 x 4 μm and 2-50 nm in height.

-

Scan the sample with area of about 4 x 4 μm and 2-50 nm in height.
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Figure 27. AFM (Atomic force microscopy) image of GDNPs 2
4.5 Data Analysis
Sucrose gradient ultracentrifuge methods showed two concentrated bands,
8/30% (band 1) and 30/45% (band 2). Photon correlation spectroscopy (PCS) was used
to measure size distribution and zeta potential of the GDNPs. The average nanoparticle
size of band 2 was approximately ~115.8 nm in radius (Figure 24). An approximate zeta
potential value was ~12 mV at pH 6 for band 2 (Figure 25). Transmission electron
microscopy (TEM) and atomic force microscopy (AFM) analysis also confirmed
successful isolation and characterization of stable GDNPs (Figures 26 and 27). In vitro
stability test for GDNPs 2 confirmed the tolerance of the nanoparticle within harsh
environment such as gastric and intestinal tract. Precisely measured particle size and
zeta potential of GDNPs 2 ensure the capability to be used as stable drug carrier in
human system. Also, TEM and AFM probed ability of GDNPs 2’s electromechanical
functionality which is critical for characterization for biological materials.
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5 PREPARATION AND CHARACTERIZATION OF GINGER LIPID-DERIVED
NANOPARTICLES FOR COLON-TARGETED SIRNA DELIVERY
Copyright © 2022, Published by the Bio-protocol,
DOI.ORG/10.21769/BioProtoc.3685
5.1 Abstract
Synthetic nanoparticle-based drug delivery system is widely known for its ability
to increase the efficacy and specificity of loaded drugs, but it often suffers from higher
immunotoxicity, and higher costs as compared to traditional drug formulations.
Contrarily, plant-derived nanoparticles appear to be free from these limitations of
synthetic nanoparticles; they are naturally occurring biocompatible vesicles that do not
generate immunotoxicity and are easy to obtain. Additionally, lipids isolated from plantderived nanoparticles have shown the capability of assembling themselves to spherical
nano-sized liposomal particles. Herein, we employ lipids extracted from ginger-derived
nanoparticles and load them with therapeutic siRNA (CD98-siRNA) to create CD98siRNA/ginger-lipid nanoparticles. Characterization of the CD98-siRNA/ginger-lipid
nanoparticles showed that they present a spherical shape, with a diameter of around
189.5 nm. The surface zeta potential of the nanoparticles varies from -18.1 to -18.4 mV.
Furthermore, in recent research, the CD98-siRNA/ginger-lipid nanoparticles have
shown specific colon targeting capability and excellent anti-inflammatory efficacy in a
Dextran Sodium Sulfate (DSS) induced mouse model of colitis.
5.2 Introduction
Small interference RNAs (siRNAs) are a type of promising therapeutic agents
that can treat various diseases by silencing the abnormally upregulated messenger

NEW THERAPEUTIC TO TREAT COLITIS

81

RNAs (mRNAs) (Nikam and Gore, 2018). Despite the effectiveness of siRNAs, the safe
and efficient delivery of the siRNAs to the therapeutic targets is still a challenging task
(Tatiparti et al., 2017). Studies have shown that artificially synthesized nanoparticles
can be used to target low doses of siRNAs to specific colonic cell types (e.g., epithelial
cells and macrophages) (Zhang et al., 2016b). However, artificially synthetic
nanoparticles have several limitations, such as potential in vivo immune toxicity and
formidable production cost. What is currently needed is a safer and more economical
platform for siRNA-based drug delivery.
Our laboratory and others have recently shown that plant-derived nanoparticles
are capable of specifically target the colon, and these naturally occurring nanoparticles
are safer and cheaper than synthetic nanoparticles (Zhang et al., 2016a). Additionally,
we can extract lipids from these plant-derived nanoparticles and reassemble them to
siRNA-incorporated nanoparticles, creating a colon-targeting siRNA/lipid nanoparticle
(Zhang et al., 2017). In the following protocol, we will use ginger-derived nanoparticles
and CD98-siRNA as starting materials to demonstrate the process of making CD98
siRNA nanoparticles (CD98-siRNA/ginger-lipid). The nanoparticles prepared in this
protocol have shown its effectiveness in treating ulcerative colitis in recent research
(Zhang et al., 2017).
5.3 Materials, Reagents, and Equipment
•

Pipette tips:
0.1-10 µl (Sorenson Bioscience, catalog number: 70600)
1-200 µl (Sorenson Bioscience, catalog number: 70520)
100-1,000 µl (Sorenson Bioscience, catalog number: 70540)
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•

1.5 ml Eppendorf Safe-Lock tubes (Eppendorf, catalog number: 0 22363204)

•

22 ml culture tubes, borosilicate glass (VWR, catalog number: 47729-580)

•

15 ml conical tubes (Denville Scientific, catalog number: C1018-P)

•

50 ml conical tubes (Denville Scientific, catalog number: C1062-P)

•

Polycarbonate centrifuge tubes (Beckman Coulter, catalog number: 349622)

•

ml polystyrene cuvettes, square (Brookhaven Instruments Corps., catalog
number: BI-SCP)

•

200 nm polycarbonate membrane (Millipore, catalog number: GTTP01300)

•

Formvar®-coated

copper

grids

(Electron

Microscopy

Sciences,

number: FCF300-CU-SC)
•

Filter paper (VWR, catalog number: 28313-068)

•

Mica sheet (Electron Microscopy Sciences, catalog number: 71855-15)

•

Kimwipes (Kimberly-Clark, catalog number: 06-666)

•

Capillary cell and plastic cap (Malvern, catalog number: DTS 1070)

•

Mouse (Jackson Laboratory, model: FVB/NJ 001800)

•

Phosphate-buffered Saline (PBS) (Corning, catalog number: 21-040-CV)

•

Methanol (Sigma-Aldrich, catalog number: 34860-1L-R)

•

Dichloromethane (Sigma-Aldrich, catalog number: 650463-1L)

•

HEPES buffer pH 7.4 (Sigma-Aldrich, catalog number: F7876)

•

Negative control siRNA (Santa Cruz, catalog number: sc-37007)

•

Positive CD98 siRNA (Santa Cruz, catalog number: sc-35033)

•

Glucose (Sigma-Aldrich, catalog number: 49163)

•

TurbofectTM reagent (Thermo Fisher Scientific, catalog number: R0531)

•

Potassium chloride (KCl, Millipore, catalog number: 7447-40-7)

•

Quant-iT Ribogreen reagent (Invitrogen, catalog number: R11491)

•

Uranyl acetate (Electron Microscopy Sciences, catalog number: 22400-4)

catalog

NEW THERAPEUTIC TO TREAT COLITIS

83

•

DiR dye (DiIC18(7)) (Thermo Fisher Scientific, catalog number: D12731)

•

Amicon® ultra-15 centrifugal filter (MWCO 10,000) (Sigma-Aldrich, catalog
number: UFC 9100)

•

1% uranyl acetate solution

•

5% glucose solution

•

Pipettes: 0.5-10 μl, 10-100 μl and 100-1,000 μl (Fisher Scientific, Eppendorf,
catalog number: 13-684-251)

•

Particle size analyzer (Brookhaven Instrument Corp., model: 90Plus)

•

Zetasizer (Malvern, model: Nano-ZS90)

•

Atomic force microscopy instrument (Seiko Instrument Inc., model: SPA400)

•

Transmission electron microscope (Carl Zeiss, model: LEO 906E)

•

Milli-Q advantage A10 water purification system (Millipore-sigma, catalog
number: C10117)

•

Centrifuge (Thermo Fisher Scientific, model: Sorvalis ST16R)

•

Ultracentrifuge (Beckman Coulter, model: Optima L-90K)

•

-80 °C freezer (So-Low, model: PV85-21)

•

Sonicator (Branson, model: 3510)

•

Vortexer (Scientific Industries, model: 200-SI0236)

•

Rotary evaporator (Buchi, model: R-210)

•

Vacuum pump (Buchi, model: V-700)

•

Vacuum controller (Buchi, model: V-800)

•

Heating bath (Buchi, model: B-491)

•

Evaporating flask (Buchi, catalog number: Z402982)

•

Liposome extruder (Avanti Polar Lipids, model: Mini extruder)

•

Microplate reader (BioTek, Model: Synergy2)
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IVIS in vivo imaging system (PerkinElmer, model: IVIS Spectrum Series)

Figure 28. A representative image of liquid-liquid extraction to isolate from
GDNPs
5.4 Procedure
5.4.1 Extraction of Lipids from Ginger Derived Nanoparticles (GDNPs)
-

Prepare 1.6 ml of purified GDNPs PBS suspension (1 mg/ml, refer to Sung et al.,
2019).

-

Add 6 ml of methyl alcohol/dichloromethane (2:1) (v/v) to 1.6 ml GDNPs
suspension in a 22 ml glass culture tube and shake thoroughly.

-

Add 2 ml of dichloromethane and 2 ml of ddH2O sequentially then briefly vortex
the mixture.

-

Centrifuge the solution in a glass tube at 2,000 x g for 10 min at room
temperature (RT) for separation of aqueous and organic phases (Figure 28).

-

Remove the upper aqueous phase by pipetting.
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Collect the remaining GDNPs extracted lipid solution into a new glass culture
tube by pipetting.

-

Wash the collected samples with 0.5 ml of 1 M KCl and centrifuge at 2,000 x
g for 10 min then remove the aqueous phase. Wash again with 0.5 ml of ddH2O
with the same condition.
Note: The wash step generally includes: add the solvent, vortex for 2 min, and
centrifuge at 2,000 x g for 10 min (RT).

-

Approximately 4-5 ml of total lipids solution is acquired, and it can be stored at 20 °C for two weeks or continue to the next step.

-

Transfer the 5 ml lipid solution to a 250 ml eggplant shape flask.

-

Put the flask on a rotary evaporator for 5-10 min to remove the organic phase
(50 °C) and to form an ultra-thin ginger lipids film on the wall of the eggplant
shape (Figure 29).

Figure 29. Formation of the thin film of lipids on the bottom surface of
eggplant shaped flask by rotary evaporation
5.4.2 Generating Ginger Derived Lipid Vesicles (GDLVs) siRNA Complex by ThinFilm Hydration
-

Dissolve 3.75 nmol of target siRNA or negative control-siRNA into 300 µl of
sterile 5% glucose solution in separate flasks and vortex lightly (10 s).
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Add 6 μl TurboFectTM reagent to the siRNA glucose solution, vortex lightly (10 s),
and incubate for 15 min at RT.

-

Add the siRNA/TurboFect glucose solution to the flask which contains the ginger
lipids film (1.6 mg GDNPs).

-

Add 500 µl of 20 mM HEPES buffer (pH 7.4).

-

Sonicate (at ~42 KHz) the flask with pipetting for 5 min at RT.

-

Add 500 µl of 20 mM HEPES buffer (pH 7.4).

-

Sonicate the suspension for another 5 min (Figure 30).

-

Measure the size of the GDLVs/siRNA complex with a size analyzer.
Note: Use 1x PBS (RT) for accurate size measurement.

-

Squeeze the suspension through AVESTIN liposomes extruder (with a 200 nm
polycarbonate membrane) for about 19-21 times at about 55 °C.

-

Suspend the nanoparticles with 5 ml of autoclaved 1x PBS for the next step or
store it at -80 °C for future use

Figure 30. Formation of GDLVs/siRNA complex after sonication
5.4.3 Characterization of siRNA Loaded GDNPs (GDLVs/siRNA Complex)
siRNA loading efficiency test
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Dilute 5 µg GDLVs/siRNA complex in TE buffer to a final volume of 1 ml.

-

Add 1 ml of Quant-iT RiboGreen reagent.

-

Incubate the solution for 5 min at RT in the dark condition.

-

Measure the fluorescence of the samples with a microplate reader (excitation
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480 nm, emission 520 nm)
Evaluation of the colon-specific targeting (in vivo bio-distribution) of
GDLVs
-

Incubate 5 ml of GDLVs (0.1-1 mg/ml in PBS) with DiR dye (10 µM) for 30 min at
RT.

-

Transfer the solution to Amicon® ultra-15 centrifugal filter.

-

Centrifuge the filter at 4 °C, 5,000 x g for 30 min.

-

Retrieve the DiR-labeled GDLVs on the apical side of the tube. Reconstitute the
DiR-labeled GDLVs in a 5 ml PBS solution.

-

Prepare two groups of 12 h-fasted FVB mice (6 weeks old, female, n = 3).

-

Gavage a single dose of DiR-labeled GDLVs (0.3 mg/ml) to one group of 12 hfasted mice at different time points (4, 8, 12, and 24 h).

-

Sacrifice both groups of the mouse and collect tissue samples of various organs
(heart, liver, spleen, lung, stomach, small intestine, colon, and kidney).

-

Take ex vivo fluorescence images of the organs using IVIS Spectrum Series in
vivo imaging system (fluorescence excitation at 750 nm, emission at 800 nm).

-

Compare the fluorescence images between organ samples from mice with and
without treatment.
Targeting for delivery of functional siRNA (in vivo transfection)
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Gavage 100 µl GDLVs/siRNA solution (0.5 nmol/ml in PBS) twice (12 h apart) to
the mice.

-

After 48 h, sacrifice the mice and collect the intestine tissues for immediate tests
or store the tissues at -80 °C.

-

Perform standard real-time qPCR for CD98 mRNA with different parts from the
intestine, including duodenum, jejunum, ileum, and colon.

-

Compare the CD98 mRNA expressions in different samples from mice treated
with or without CD98 siRNA.

5.4.4 Characterization of GDLVs/siRNA Complex
Measure particle size
-

Dilute 0.2 ml of GDLVs/siRNA complex solution into 1.8 ml PBS.

-

Carefully add the diluted mixture to a cuvette, avoid producing bubbles.

-

Insert the cuvette to the particle analyzer chamber.

-

Determine the size of particles
Measure particle size

-

Carefully add 0.8 ml of GDLVs/siRNA mixture to a capillary cell.

-

Cover the capillary cell with a plastic cap.

-

Insert the cell to the chamber of zeta potential analyzer.

-

Measure the zeta-potential value at a neutral pH.
Acquire transmission electron microscopy (TEM) image

-

Directly deposit 1 µl of GDLVs/siRNA sample onto the surface of a formvarcoated grid.

-

Add 5 µl 1% uranyl acetate on top of the sample and wait for 15 s.
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Carefully absorb the sample and uranyl acetate with a disposable wiper without
touching the surface.

-

Let the sample dry for 30 min at RT.

-

Scan the sample with a transmission electron microscope.
Acquire atomic force microscopy (AFM) image

-

Deposit 5 µl of GDLVs/siRNA sample to the mica sheet.

-

Dry the sample for 2 h (at RT).

-

Gently rinse the mica sheet three times each with 20 µl of distilled water.

-

Dry the sample at RT for another 2 h.

-

Leave it for 30 min at RT until the sample becomes flat.

-

Scan the sample with an area of about 4 x 4 µm and 2-50 nm in height.

5.5 Data Analysis
TEM and AFM images show that the GDLVs are nano-sized particles and have
the spherical shape (Images can be found in Figure 2 from Zhang et al., 2017).
Dynamic light scattering analysis showed that it has about 189.5 nm in diameter
and zeta potential varies from -18.1 to -18.4 mV (Related data can be found in
supplementary data from Zhang et al., 2017).
The efficiency of siRNA loading is calculated according to a standard curve
provided by the Quant-iT RiboGreen manufacturer. Fluorescence of samples is
measured using standard fluorescence wavelength, with the excitation at 480 nm and
the emission at 520 nm.
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6 OVERALL CONCLUSION
Understanding of IBD is quickly evolving as investigations on the pathogenesis of
the disease are increasing, and the ability to target various pathways is being developed.
The current few years hold much promise for both gastroenterology clinicians and
patients, with new therapeutic options expected to be approved by FDA and introduced
into the market. Nonetheless, there remains a therapeutic barrier of numerous options
for delivery methods, efficacy, and safety. In these studies, two different approaches
were demonstrated to accelerate the healing process of epithelial damage.
Gut metabolite-mediated regulation of the intestinal barrier in the pathogenesis of
inflammation has been extensively studied in IBD patients. Analysis of fecal
metabolome showed upregulation and downregulation of specific metabolites that may
be used as therapeutic targets to treat ulcerative colitis. Although the publication on
American journal of physiology-gastrointestinal and liver physiology (page 21) showed
somewhat effective anti-inflammatory effects in vitro, there may need further
investigation in ulcerative colitis animal models to prove its effectiveness with optimized
structure and dosage of purified metabolites.
Gene delivery therapy utilizes genetic materials with the purpose of treating
diseases by transferring the vectors directly into cells. Strategies to optimize gene
delivery methods and therapeutic agents have been studied to overcome potential
adverse effects, such as the possibility of causing a tumor. If the new gene is inserted in
the wrong location in the system, there is a chance that the insertion might lead to
unexpected immunological responses and tumor formation. Results from the publication
on Biomaterials (page 41) show that oral delivery of IL-22 mRNA encapsulated within
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lipid nanoparticles accelerates the healing process of damaged intestinal mucosa
without any immunological responses. This proves that the novel oral delivery of IL22/nLNPs offers a safe and effective therapeutic strategy against UC. This novel
method can be more effective by adapting the dual drug encapsulation technique. The
co-encapsulation of two different therapeutic agents that are overexpressed or
downregulated in UC patients can be used to maximize the treatment efficiency.
Documentation of protocols in life science is vital because they provide critical
information that enables scientists to reproduce published experiments. Well-organized
protocols contain step-by-step procedures, reagent suppliers, and specific catalog
numbers, which can be an excellent resource for the scientific community. These two
peer-reviewed published protocols offer detailed procedures to generate crucial gingerderived nanoparticles (GDNPs) and ginger-derived lipid vesicles (GDLVs) that are key
studies of the development of newly generated lipid nanoparticles for IL-22 mRNA
delivery. Clear scientific protocols, as these two publications, should be encouraged to
facilitate the transfer of knowledge, equip new researchers with essential skills and
ensure that the experiments can be replicated.
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